var title_f18_36_19008="Orbital bones";
var content_f18_36_19008=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Bones of the orbit",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 340px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing depicts the major bones of the orbit.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_36_19008=[""].join("\n");
var outline_f18_36_19008=null;
var title_f18_36_19009="Patient information: Vaginismus (The Basics)";
var content_f18_36_19009=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?10/60/11202\">",
"         Patient information: Pelvic muscle (Kegel) exercises (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/17/11538\">",
"         Patient information: Sex problems in women (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?12/4/12357\">",
"         Patient information: Sexual problems in women (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Vaginismus (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/vaginismus-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H29965016\">",
"      <span class=\"h1\">",
"       What is vaginismus?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Vaginismus is a condition that happens when the muscles around the opening to the vagina tighten up. The muscles tighten when something is about to be put in the vagina, such as a penis, tampon, or medical device. Vaginismus causes pain during sex. A woman might also have pain if a doctor or nurse does a pelvic exam.",
"     </p>",
"     <p>",
"      Vaginismus can happen if a woman has problems with a partner or relationship, or had a bad experience with sex in the past. It can also happen if a woman has an infection or other medical condition in the vagina.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29965031\">",
"      <span class=\"h1\">",
"       What are the symptoms of vaginismus?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptom of vaginismus is pain when something is put in the vagina, such as a penis, finger, tampon, or medical device. Sometimes, the pain is so bad that nothing can be put in the vagina.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29965046\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If having sex is painful, see your doctor or nurse. He or she can look for the cause. If you feel pain during a pelvic exam, let the doctor or nurse know when you feel it and where the pain is. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29965061\">",
"      <span class=\"h1\">",
"       Is there a test for vaginismus?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no specific test. Your doctor or nurse can usually tell if you have it by learning about your symptoms and doing an exam. He or she might be able to feel the muscles around the opening to your vagina tighten during an exam.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29965076\">",
"      <span class=\"h1\">",
"       How is vaginismus treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Treatment for any medical condition that is causing pain, such as an infection or skin irritation",
"       </li>",
"       <li>",
"        Exercises to help relax the tight muscles",
"       </li>",
"       <li>",
"        Physical therapy to loosen the muscles around your vagina",
"       </li>",
"       <li>",
"        Devices called &ldquo;dilators&rdquo; you place in your vagina &ndash; These can help you get used to having something in the vagina. You can put numbing medicine on them so they do not hurt. Using dilators can help your body get used to having something put in the vagina without pain. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29965091\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/17/11538?source=see_link\">",
"       Patient information: Sex problems in women (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/60/11202?source=see_link\">",
"       Patient information: Pelvic muscle (Kegel) exercises (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/4/12357?source=see_link\">",
"       Patient information: Sexual problems in women (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?18/36/19009?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83177 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-89768E4622-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_36_19009=[""].join("\n");
var outline_f18_36_19009=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29965016\">",
"      What is vaginismus?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29965031\">",
"      What are the symptoms of vaginismus?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29965046\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29965061\">",
"      Is there a test for vaginismus?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29965076\">",
"      How is vaginismus treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29965091\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/60/11202?source=related_link\">",
"      Patient information: Pelvic muscle (Kegel) exercises (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/17/11538?source=related_link\">",
"      Patient information: Sex problems in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/4/12357?source=related_link\">",
"      Patient information: Sexual problems in women (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_36_19010="X-ray fracture of lumbar transverse process";
var content_f18_36_19010=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    X-ray fracture of lumbar transverse process",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The plain film tomogram of the left sided transverse processes of the lumbar spine in the AP projection reveals transverse fractures of the L3 and L4 vertebra (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, 3rd Edition. Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_36_19010=[""].join("\n");
var outline_f18_36_19010=null;
var title_f18_36_19011="Acetic acid: Drug information";
var content_f18_36_19011=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acetic acid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/37/15956?source=see_link\">",
"    see \"Acetic acid: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/39/42610?source=see_link\">",
"    see \"Acetic acid: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F129880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Otic Agent, Anti-infective;",
"     </li>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F129874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Irrigation",
"     </b>",
"     (",
"     <b>",
"      Note:",
"     </b>",
"     Dosage of an irrigating solution depends on the capacity or surface area of the structure being irrigated):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     For continuous irrigation of the urinary bladder with 0.25% acetic acid irrigation, the rate of administration will approximate the rate of urine flow; usually 500-1500 mL/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     For periodic irrigation of an indwelling urinary catheter to maintain patency, about 50 mL of 0.25% acetic acid irrigation is required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Otitis externa:",
"     </b>",
"     Otic: Insert saturated wick; keep moist 24 hours; remove wick and instill 5 drops 3-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F10110810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/39/42610?source=see_link\">",
"      see \"Acetic acid: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Otitis externa:",
"     </b>",
"     Otic: Children &ge;3 years: Insert saturated wick; keep moist 24 hours; remove wick and instill 5 drops 3-4 times/day.",
"     <b>",
"      Note:",
"     </b>",
"     3-4 drops may be sufficient in children due to the smaller capacity of the ear canal.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F129875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F129865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for irrigation: 0.25% (1000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for irrigation [preservative free]: 0.25% (250 mL, 500 mL, 1000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, otic [drops]: 2% (15 mL, 60 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F129856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F129867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not for internal intake or I.V. infusion; topical use or irrigation use only.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F129866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Irrigation of the bladder; periodic irrigation of indwelling catheters; treatment of superficial bacterial infections of the external auditory canal",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F129885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Acetic acid for irrigation may be confused with glacial acetic acid",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       VoSol&reg; may be confused with Vexol&reg;,VoSol&reg; HC",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F129879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Irrigation solution:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; Metabolic: Systemic acidosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urologic pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Otic solution:",
"     </b>",
"     Otic: Irritation, burning, stinging",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F129869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acetic acid or any component of the formulation; during transurethral procedures (irrigation); perforated tympanic membrane (otic solution)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F129859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bladder irritation: Use of irrigation in patients with mucosal lesions of urinary bladder may cause irritation. Open lesions of the bladder mucosa may result in systemic acidosis from absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Not for internal intake or I.V. infusion; topical use or irrigation use only.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6217531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F129862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13332938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Systemic absorption following bladder irrigation is not likely unless open lesions are present.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13332939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in breast-feeding women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Fem pH Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9-0.025% (50 g): $24.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Relagard Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9-0.025% (50 g): $19.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Acetic Acid)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50% (3785 mL): $56.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Acetic Acid Irrigation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (1000 mL): $2.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Acetic Acid Otic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (15 mL): $40.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Acetic Acid-Aluminum Acetate Otic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (60 mL): $72.00",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aquaear (AU);",
"     </li>",
"     <li>",
"      Earcalm (GB, IE);",
"     </li>",
"     <li>",
"      Suym Otico (PE);",
"     </li>",
"     <li>",
"      Vosol (NZ)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Kawamata M, Fujita S, and Mayumi T, &ldquo;Acetic Acid Intoxication by Rectal Administration,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1994, 32(3):333-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/36/19011/abstract-text/8007044/pubmed\" id=\"8007044\" target=\"_blank\">",
"        8007044",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Penner GE, &ldquo;Acid Ingestion: Toxicology and Treatment,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1980, 9(7):374-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/36/19011/abstract-text/7396252/pubmed\" id=\"7396252\" target=\"_blank\">",
"        7396252",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9277 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-D201336892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_36_19011=[""].join("\n");
var outline_f18_36_19011=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129880\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129874\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10110810\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129875\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129865\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129856\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129867\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129866\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129885\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129879\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129869\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129859\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298674\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6217531\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129862\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13332938\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13332939\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322962\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539808\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9277\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9277|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/37/15956?source=related_link\">",
"      Acetic acid: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/39/42610?source=related_link\">",
"      Acetic acid: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_36_19012="Postop fat necrosis";
var content_f18_36_19012=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Post operative fat necrosis presenting as a palpable lump",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 423px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral MLO views of TRAM flap reconstructed breasts. Coarse, lucent centered dystrophic calcifications are seen in a bizarre pattern in both breasts consistent with bilateral fat necrosis presenting as a palpable lump.",
"    <div class=\"footnotes\">",
"     MLO: mediolateral oblique; TRAM: transverse rectus abdominis myocutaneous.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_36_19012=[""].join("\n");
var outline_f18_36_19012=null;
var title_f18_36_19013="Thioridazine: Patient drug information";
var content_f18_36_19013=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Thioridazine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"     see \"Thioridazine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/11/7350?source=see_link\">",
"     see \"Thioridazine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700590",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may change the electrical activity in your heart. This change could cause fast heartbeats. This drug does not mix well with many drugs. Check all drugs with your doctor before starting this drug. If you have a history of fast heartbeats, tell your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700570",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a higher chance of death in older adults who take this drug for mental problems caused by dementia. Most of the deaths were linked to heart disease or infection. This drug is not approved to treat mental problems caused by dementia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat schizophrenia. It may take 6 weeks to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to thioridazine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703824",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have very bad heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stop fluoxetine for at least 5 weeks before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697188",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bone marrow disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have Parkinson's disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness, trouble moving around, or stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698579",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will need an ECG before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11088 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-B63444C5D6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_36_19013=[""].join("\n");
var outline_f18_36_19013=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026329\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026331\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026330\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026335\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026336\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026338\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026333\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026334\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026339\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026340\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=related_link\">",
"      Thioridazine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/11/7350?source=related_link\">",
"      Thioridazine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_36_19014="Management of osteochondritis dissecans (OCD)";
var content_f18_36_19014=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of osteochondritis dissecans (OCD)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/36/19014/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/36/19014/contributors\">",
"     Albert C Hergenroeder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/36/19014/contributors\">",
"     Brian S Harvey, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/36/19014/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/36/19014/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/36/19014/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/36/19014/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/36/19014/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H313966\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteochondritis dissecans (OCD) refers to osteonecrosis of subchondral bone and most often occurs in the knee, elbow, or ankle of school-age and adolescent children where it causes pain. Plain radiographs are frequently diagnostic. Sports medicine and orthopedic specialists usually determine the staging and stability of OCD lesions by magnetic resonance imaging. Initial treatment of stable lesions typically consists of rest, nonsteroidal antiinflammatory medicines, avoidance of high intensity activities, and physical therapy. Patients who are skeletally immature frequently do well with nonoperative therapy. Patients who have large lesions or develop intraarticular foreign bodies usually need surgery.",
"   </p>",
"   <p>",
"    This topic will discuss the management of OCD. The clinical manifestations and diagnosis of OCD and other causes of knee, elbow, or ankle pain in the young athlete are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13913?source=see_link\">",
"       \"Clinical manifestations and diagnosis of osteochondritis dissecans (OCD)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28455?source=see_link\">",
"       \"Traumatic causes of acute knee pain and injury in the young athlete\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22937?source=see_link\">",
"       \"Elbow injuries in the young athlete\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31050?source=see_link\">",
"       \"Clinical features and management of ankle pain in the young athlete\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H314565\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteochondritis dissecans (OCD) is defined as osteonecrosis of subchondral bone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19014/abstract/1\">",
"     1",
"    </a>",
"    ]. Specifically, OCD is a localized lesion in which a segment of subchondral bone and articular cartilage separates from the underlying bone, leaving either a stable or unstable fragment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19014/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several classification systems for OCD lesions that are based upon plain radiograph, magnetic resonance imaging, or arthroscopic findings as shown in the table (",
"    <a class=\"graphic graphic_table graphicRef85755 \" href=\"UTD.htm?7/19/7484\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19014/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. On plain radiograph, the severity of the OCD lesion is defined according to Berndt and Harty as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19014/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I - Small compressed, nondisplaced fragment",
"     </li>",
"     <li>",
"      Stage II - Partially detached fragment",
"     </li>",
"     <li>",
"      Stage III - Completely detached, nondisplaced foreign body",
"     </li>",
"     <li>",
"      Stage IV - Completely detached and displaced foreign body",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Juvenile OCD refers to the presence of the lesion in patients with open physes (growth plates (",
"    <a class=\"graphic graphic_figure graphicRef79444 \" href=\"UTD.htm?26/18/26918\">",
"     figure 1",
"    </a>",
"    )) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19014/abstract/6\">",
"     6",
"    </a>",
"    ]. Adult OCD describes the condition in skeletally mature patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H314655\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suggestive clinical findings of OCD include gradually worsening joint pain over several months in active patients or, for OCD of the talus, lingering pain after an ankle inversion injury. Bony tenderness over the typical locations (medial femoral condyle, anterolateral elbow, or medial or lateral talar dome), or, with advanced disease, popping, catching, or locking of the joint may be present. The diagnosis of OCD can frequently be made based upon plain radiographic findings of the characteristic bony fragment (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85768 \" href=\"UTD.htm?3/18/3362\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85769 \" href=\"UTD.htm?2/41/2704\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85770 \" href=\"UTD.htm?42/18/43298\">",
"     image 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13913?source=see_link&amp;anchor=H2510199#H2510199\">",
"     \"Clinical manifestations and diagnosis of osteochondritis dissecans (OCD)\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with typical clinical and radiographic findings of OCD, magnetic resonance imaging (MRI) is not needed to establish the diagnosis but is necessary to stage the lesion (",
"    <a class=\"graphic graphic_table graphicRef85755 \" href=\"UTD.htm?7/19/7484\">",
"     table 1",
"    </a>",
"    ), or in some patients, to exclude other joint pathology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13913?source=see_link&amp;anchor=H17944402#H17944402\">",
"     \"Clinical manifestations and diagnosis of osteochondritis dissecans (OCD)\", section on 'Magnetic resonance imaging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13913?source=see_link&amp;anchor=H21753968#H21753968\">",
"     \"Clinical manifestations and diagnosis of osteochondritis dissecans (OCD)\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6044707\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR SUBSPECIALTY REFERRAL OR CONSULTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for sports medicine or orthopedic specialty referral primarily depends upon the likelihood that the OCD lesion will not heal with nonoperative therapy. Healing is largely determined by skeletal maturity, characteristics of the OCD lesion (ie, size or stability), and the joint affected [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19014/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following patients with OCD warrant referral to a sports medicine or orthopedic specialist:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skeletally immature patients (ie, open growth plates) with unstable (ie, partially or completely detached) OCD lesions of the knee or elbow (Stage II, III, or IV, (",
"      <a class=\"graphic graphic_table graphicRef85755 \" href=\"UTD.htm?7/19/7484\">",
"       table 1",
"      </a>",
"      )) based upon on plain radiographs, magnetic resonance imaging, or both.",
"     </li>",
"     <li>",
"      Skeletally immature patients with large, stable (Stage 1) lesions (parameters for the knee include &gt;2 cm in length, &gt;6 percent scaled surface area on MRI, or &gt;200 mm",
"      <sup>",
"       2",
"      </sup>",
"      surface area on MRI; for the elbow lesions affecting &gt;50 percent of the capitellum surface) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/36/19014/abstract/7-10\">",
"       7-10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Skeletally immature patients with clinical findings of a loose foreign body in the joint (eg, locking or catching)",
"     </li>",
"     <li>",
"      Skeletally mature patients (ie, closed growth plates) regardless of affected joint, lesion size, or stage",
"     </li>",
"     <li>",
"      Patients who have persistent or worsening signs and symptoms despite nonoperative management",
"     </li>",
"     <li>",
"      All patients with OCD of the joints other than the knee or elbow",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Skeletally immature children with stable lesions that are small (parameters for the knee are &lt;2 cm in length, &lt;6 percent scaled surface area or &lt;200 mm",
"    <sup>",
"     2",
"    </sup>",
"    on MRI; for the elbow lesions affecting &lt;50 percent of the capitellum surface) and located in the knee or elbow often do well with nonoperative therapy alone and can frequently be treated by a knowledgeable primary care provider who is comfortable with overseeing the selected form of immobilization (casting, splinting, or brace) and ordering the necessary follow-up imaging to determine healing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H315746\">",
"    <span class=\"h1\">",
"     NONOPERATIVE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nonoperative management of OCD is based upon case series and expert opinion and consists of restriction of activities, immobilization, and physical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19014/abstract/9\">",
"     9",
"    </a>",
"    ]. We suggest that children with Stage I, II, or III juvenile osteochondritis dissecans of the knee, elbow, or ankle initially undergo nonoperative therapy rather than surgical repair (",
"    <a class=\"graphic graphic_table graphicRef85755 \" href=\"UTD.htm?7/19/7484\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19014/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. Skeletally immature patients with an intraarticular foreign body (Stage IV lesion) warrant timely surgery to prevent permanent joint damage. (See",
"    <a class=\"local\" href=\"#H315785\">",
"     'Surgical treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Depending upon the disease stage (",
"    <a class=\"graphic graphic_table graphicRef85755 \" href=\"UTD.htm?7/19/7484\">",
"     table 1",
"    </a>",
"    ), healing rates with nonoperative management of juvenile OCD vary from approximately 50 to more than 90 percent for lesions in the knee or elbow and approximately 45 to 60 percent for the talus (ankle) with the highest healing rates occurring in patients with Stage I OCD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19014/abstract/2,8,9,11-13\">",
"     2,8,9,11-13",
"    </a>",
"    ]. Nonoperative treatment is a reasonable first option for patients with adult OCD who have small, stable (Stage I or II) lesions (",
"    <a class=\"graphic graphic_table graphicRef85755 \" href=\"UTD.htm?7/19/7484\">",
"     table 1",
"    </a>",
"    ) although the likelihood of healing is approximately 50 percent or less",
"   </p>",
"   <p>",
"    Nonoperative management includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Restriction of activity (see",
"      <a class=\"local\" href=\"#H9419138\">",
"       'Restriction of activities'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Immobilization (see",
"      <a class=\"local\" href=\"#H315754\">",
"       'Immobilization'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Physical therapy (see",
"      <a class=\"local\" href=\"#H315762\">",
"       'Physical therapy'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Resolution of pain and documented healing of the subchondral bone guide the duration of nonoperative treatment and determine when the athlete can resume activities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9419138\">",
"    <span class=\"h2\">",
"     Restriction of activities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limitation of activity during nonoperative treatment is of critical importance. Once diagnosed, the athlete should be removed from sports and should not return until resolution of symptoms and evidence of healing on imaging has occurred. Rest is initially enforced through immobilization for 6 to 12 weeks. The duration of immobilization depends upon clinical response. (See",
"    <a class=\"local\" href=\"#H315754\">",
"     'Immobilization'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For OCD of the knee or ankle, once immobilization has occurred and healing is evident, the patient should receive physical therapy (PT) designed to increase strength and mobility at the joint and should begin ambulation. Swimming and cycling are additional activities that can help build strength and mobility while putting less impact on the knee or ankle. Slow return to sports may begin once the patient is asymptomatic, has completed PT, and has no pain with running, sprinting or cutting which typically takes six months [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19014/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H315762\">",
"     'Physical therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Rest for OCD of the elbow includes no throwing, repetitive overhead movements, or elbow impact sports (eg, gymnastics) along with immobilization and PT [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19014/abstract/10\">",
"     10",
"    </a>",
"    ]. Timing for return to play depends upon the response of the lesion to nonoperative therapy and, as for OCD of the knee or ankle, typically occurs at six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H315754\">",
"    <span class=\"h2\">",
"     Immobilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with juvenile OCD who are undergoing nonoperative treatment typically receive immobilization by cast, splint or knee immobilizer, hinged brace (knee or elbow), or a controlled ankle motion (CAM&reg;) walker boot until pain and radiographic evidence of healing is present. Casting may be preferred when adherence to immobilization in a very active athlete is",
"    <strong>",
"     not",
"    </strong>",
"    assured. The typical duration of initial immobilization is four to six weeks. If symptoms are not resolved or radiographic healing is not evident by six weeks, some experts suggest one week of cast or splint removal with physical therapy to decrease the potential for contractions and atrophy followed by a second four to six week period of casting or splinting.",
"   </p>",
"   <p>",
"    Initial immobilization varies based upon the joint involved:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Knee",
"      </strong>",
"      &ndash; Nonweightbearing cast or long leg knee immobilizer with partial weight bearing with crutch assistance",
"     </li>",
"     <li>",
"      <strong>",
"       Elbow",
"      </strong>",
"      &ndash; Long arm cast, splint, or hinged elbow brace locked into slight flexion",
"     </li>",
"     <li>",
"      <strong>",
"       Ankle",
"      </strong>",
"      &ndash; Stage I lesions (",
"      <a class=\"graphic graphic_table graphicRef85755 \" href=\"UTD.htm?7/19/7484\">",
"       table 1",
"      </a>",
"      ): splint or brace, Stage II lesions: cast or below the knee controlled ankle motion (CAM&reg;) walker",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once initial immobilization has resulted in healing, we continue bracing during recovery and physical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H315762\">",
"    <span class=\"h2\">",
"     Physical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical therapy (PT) improves strength, mobility, and flexibility of the affected joint and is also important to counteract atrophy and contractions associated with immobilization [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19014/abstract/2,11,14\">",
"     2,11,14",
"    </a>",
"    ]. PT should improve both active and passive range of motion of the affected joint and should commence once the patient has resolution of pain and evidence of bony healing on imaging.",
"   </p>",
"   <p>",
"    Joint-specific goals of PT include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Knee",
"      </strong>",
"      &ndash; Stretching of the quadriceps and hamstring muscles, improved quadriceps and core abdominal muscle strength, including the multifidus, transverse abdominus and gluteus medius.",
"     </li>",
"     <li>",
"      <strong>",
"       Elbow",
"      </strong>",
"      &ndash; Scapulothoracic stabilization and strengthening (eg, conditioning of the rhomboid; upper, mid, and lower trapezius; levator scapulae, and serratus anterior muscles) and rotator cuff muscle strengthening to help decrease the valgus load at the elbow during repetitive overhead and throwing motions",
"     </li>",
"     <li>",
"      <strong>",
"       Ankle",
"      </strong>",
"      &ndash; Strengthening of the ankle stabilizers (eg, conditioning of the tibialis anterior, peroneus longus, peroneus brevis, and tibialis posterior muscles, and the gastrocnemius and soleus complex) and improved proprioception (eg, balancing exercises and strengthening of core and gluteus medius muscles)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3267112\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rest and immobilization are the primary treatments for pain caused by OCD. Nonsteroidal antiinflammatory drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ) may be used for short-term pain relief during the first three days of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H315785\">",
"    <span class=\"h1\">",
"     SURGICAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The operative management of OCD is based upon case series and expert opinion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19014/abstract/9\">",
"     9",
"    </a>",
"    ]. Evidence that compares outcomes among the different types of operative treatment is lacking. Children with juvenile OCD that have a loose foreign body (Stage IV) or have not responded to four to six months of nonoperative therapy and most patients with adult OCD warrant surgical repair. Nonoperative treatment is a reasonable first option for patients with adult OCD who have small, stable (Stage I or II) lesions (",
"    <a class=\"graphic graphic_table graphicRef85755 \" href=\"UTD.htm?7/19/7484\">",
"     table 1",
"    </a>",
"    ) although the likelihood of healing is approximately 50 percent or less [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19014/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H315746\">",
"     'Nonoperative treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are multiple surgical techniques for OCD that include arthroscopic drilling, metallic screw fixation, bioabsorbable fixation, microfracture, and chondrocyte transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19014/abstract/2,11,14-20\">",
"     2,11,14-20",
"    </a>",
"    ]. The choice of technique depends upon the patient&rsquo;s skeletal maturity, the stage of the OCD fragment (",
"    <a class=\"graphic graphic_table graphicRef85755 \" href=\"UTD.htm?7/19/7484\">",
"     table 1",
"    </a>",
"    ), and the size of the lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19014/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6045191\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving nonoperative treatment typically undergo clinical evaluation every two weeks while being immobilized. We obtain plain radiographs at 6 weeks and 12 weeks to assess for bony healing. Patients with radiographic improvement at 12 weeks should undergo clinical evaluation and follow-up radiographs every three months until full healing is documented. Patients who do not show radiographic evidence of healing at 12 weeks warrant referral to an orthopedic surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19014/abstract/7,9\">",
"     7,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6045199\">",
"    <span class=\"h1\">",
"     RETURN TO ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before returning to competition, the patient should be pain free with return of full active range of motion, strength, and endurance. The timing for return to play varies by lesion location, lesion stage (",
"    <a class=\"graphic graphic_table graphicRef85755 \" href=\"UTD.htm?7/19/7484\">",
"     table 1",
"    </a>",
"    ), rate of improvement, and type of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19014/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients who rapidly respond to nonoperative treatment may return to activity as early as 12 weeks. However, return to play may be delayed as long as six months or longer in other patients in whom healing is delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19014/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our experience, patients with complete healing after surgical treatment typically can return to play within six months to one year of diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6044728\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with complete healing of OCD should have full recovery of joint function. Complete healing is most commonly seen in skeletally immature patients with Stage I or II lesions of the knee or elbow (",
"    <a class=\"graphic graphic_table graphicRef85755 \" href=\"UTD.htm?7/19/7484\">",
"     table 1",
"    </a>",
"    ). These lesions have rates of healing that approach 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19014/abstract/2,8,9,11,21,22\">",
"     2,8,9,11,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, skeletally mature patients and patients with Stage III or IV lesions are less likely to have complete healing and approximately 50 percent of these patients are at risk for chronic pain, mechanical symptoms, and arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19014/abstract/7,9,21,23,24\">",
"     7,9,21,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6045183\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteochondritis dissecans (OCD) is defined as osteonecrosis of subchondral bone. Specifically, OCD is a localized lesion in which a segment of subchondral bone and articular cartilage separates from the underlying bone, leaving either a stable or unstable fragment. (See",
"      <a class=\"local\" href=\"#H314565\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Juvenile OCD refers to the presence of the lesion in patients with open physes (growth plates (",
"      <a class=\"graphic graphic_figure graphicRef79444 \" href=\"UTD.htm?26/18/26918\">",
"       figure 1",
"      </a>",
"      )) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/36/19014/abstract/6\">",
"       6",
"      </a>",
"      ]. Adult OCD describes the condition in skeletally mature patients. (See",
"      <a class=\"local\" href=\"#H314565\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are several classification systems for OCD lesions that are based upon plain radiograph, magnetic resonance imaging, or arthroscopic findings as shown in the table (",
"      <a class=\"graphic graphic_table graphicRef85755 \" href=\"UTD.htm?7/19/7484\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H314565\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The need for specialty referral primarily depends upon the likelihood that the OCD lesion will not heal with nonoperative therapy. Healing is largely determined by skeletal maturity, characteristics of the OCD lesion (ie, size or stability), and the joint affected. Specific indications for specialty referral are presented. (See",
"      <a class=\"local\" href=\"#H6044707\">",
"       'Indications for subspecialty referral or consultation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that children with Stage I, II, or III juvenile osteochondritis dissecans of the knee, elbow, or ankle initially undergo nonoperative therapy consisting of rest, immobilization, and physical therapy rather than surgical repair (",
"      <a class=\"graphic graphic_table graphicRef85755 \" href=\"UTD.htm?7/19/7484\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Nonoperative treatment is also a reasonable first option for patients with adult OCD who have small, stable (Stage I or II) lesions. (See",
"      <a class=\"local\" href=\"#H315746\">",
"       'Nonoperative treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with juvenile OCD that have a loose foreign body (Stage IV) or have not responded to four to six months of nonoperative therapy and most patients with adult OCD warrant surgical repair. (See",
"      <a class=\"local\" href=\"#H315785\">",
"       'Surgical treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19014/abstract/1\">",
"      Petrie PW. Aetiology of osteochondritis dissecans. Failure to establish a familial background. J Bone Joint Surg Br 1977; 59:366.",
"     </a>",
"    </li>",
"    <li>",
"     DeLee JC, Drez Jr D, Miller MD. DeLee &amp; Drez's Orthopaedic Sports Medicine Principles and Practice, 2nd, Elsevier Science, Philadelphia 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19014/abstract/3\">",
"      BERNDT AL, HARTY M. Transchondral fractures (osteochondritis dissecans) of the talus. J Bone Joint Surg Am 1959; 41-A:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19014/abstract/4\">",
"      Dipaola JD, Nelson DW, Colville MR. Characterizing osteochondral lesions by magnetic resonance imaging. Arthroscopy 1991; 7:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19014/abstract/5\">",
"      Guhl JF. Arthroscopic treatment of osteochondritis dissecans. Clin Orthop Relat Res 1982; :65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19014/abstract/6\">",
"      Robertson W, Kelly BT, Green DW. Osteochondritis dissecans of the knee in children. Curr Opin Pediatr 2003; 15:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19014/abstract/7\">",
"      Edmonds EW, Polousky J. A Review of Knowledge in Osteochondritis Dissecans: 123 Years of Minimal Evolution from K&ouml;nig to the ROCK Study Group. Clin Orthop Relat Res 2013; 471:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19014/abstract/8\">",
"      Wall EJ, Vourazeris J, Myer GD, et al. The healing potential of stable juvenile osteochondritis dissecans knee lesions. J Bone Joint Surg Am 2008; 90:2655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19014/abstract/9\">",
"      Chambers HG, Shea KG, Carey JL. AAOS Clinical Practice Guideline: diagnosis and treatment of osteochondritis dissecans. J Am Acad Orthop Surg 2011; 19:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19014/abstract/10\">",
"      Takahara M, Mura N, Sasaki J, et al. Classification, treatment, and outcome of osteochondritis dissecans of the humeral capitellum. J Bone Joint Surg Am 2007; 89:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19014/abstract/11\">",
"      Polousky JD. Juvenile osteochondritis dissecans. Sports Med Arthrosc 2011; 19:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19014/abstract/12\">",
"      Perumal V, Wall E, Babekir N. Juvenile osteochondritis dissecans of the talus. J Pediatr Orthop 2007; 27:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19014/abstract/13\">",
"      Tol JL, Struijs PA, Bossuyt PM, et al. Treatment strategies in osteochondral defects of the talar dome: a systematic review. Foot Ankle Int 2000; 21:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19014/abstract/14\">",
"      Kocher MS, Tucker R, Ganley TJ, Flynn JM. Management of osteochondritis dissecans of the knee: current concepts review. Am J Sports Med 2006; 34:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19014/abstract/15\">",
"      De Smet AA, Ilahi OA, Graf BK. Reassessment of the MR criteria for stability of osteochondritis dissecans in the knee and ankle. Skeletal Radiol 1996; 25:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19014/abstract/16\">",
"      Ruch DS, Cory JW, Poehling GG. The arthroscopic management of osteochondritis dissecans of the adolescent elbow. Arthroscopy 1998; 14:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19014/abstract/17\">",
"      Gudas R, Simonaityte R, Cekanauskas E, Tamosi��nas R. A prospective, randomized clinical study of osteochondral autologous transplantation versus microfracture for the treatment of osteochondritis dissecans in the knee joint in children. J Pediatr Orthop 2009; 29:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19014/abstract/18\">",
"      Edmonds EW, Albright J, Bastrom T, Chambers HG. Outcomes of extra-articular, intra-epiphyseal drilling for osteochondritis dissecans of the knee. J Pediatr Orthop 2010; 30:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19014/abstract/19\">",
"      Tabaddor RR, Banffy MB, Andersen JS, et al. Fixation of juvenile osteochondritis dissecans lesions of the knee using poly 96L/4D-lactide copolymer bioabsorbable implants. J Pediatr Orthop 2010; 30:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19014/abstract/20\">",
"      Steinhagen J, Bruns J, Deuretzbacher G, et al. Treatment of osteochondritis dissecans of the femoral condyle with autologous bone grafts and matrix-supported autologous chondrocytes. Int Orthop 2010; 34:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19014/abstract/21\">",
"      Matsuura T, Kashiwaguchi S, Iwase T, et al. Conservative treatment for osteochondrosis of the humeral capitellum. Am J Sports Med 2008; 36:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19014/abstract/22\">",
"      Mihara K, Suzuki K, Makiuchi D, et al. Surgical treatment for osteochondritis dissecans of the humeral capitellum. J Shoulder Elbow Surg 2010; 19:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19014/abstract/23\">",
"      Takahara M, Ogino T, Fukushima S, et al. Nonoperative treatment of osteochondritis dissecans of the humeral capitellum. Am J Sports Med 1999; 27:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19014/abstract/24\">",
"      Takahara M, Ogino T, Sasaki I, et al. Long term outcome of osteochondritis dissecans of the humeral capitellum. Clin Orthop Relat Res 1999; :108.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85774 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-2.133.93.82-E575B2020D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_36_19014=[""].join("\n");
var outline_f18_36_19014=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6045183\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H313966\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H314565\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H314655\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6044707\">",
"      INDICATIONS FOR SUBSPECIALTY REFERRAL OR CONSULTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H315746\">",
"      NONOPERATIVE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9419138\">",
"      Restriction of activities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H315754\">",
"      Immobilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H315762\">",
"      Physical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3267112\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H315785\">",
"      SURGICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6045191\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6045199\">",
"      RETURN TO ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6044728\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6045183\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/85774\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/85774|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/18/3362\" title=\"diagnostic image 1\">",
"      Osteochondritis dissecans of the knee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/41/2704\" title=\"diagnostic image 2\">",
"      Osteochondritis dissecans of the elbow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/18/43298\" title=\"diagnostic image 3\">",
"      Osteochondritis dissecans of the ankle - medial talus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/85774|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/18/26918\" title=\"figure 1\">",
"      Growth plate anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/85774|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/19/7484\" title=\"table 1\">",
"      Classification of osteochondritis dissecans",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31050?source=related_link\">",
"      Clinical features and management of ankle pain in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13913?source=related_link\">",
"      Clinical manifestations and diagnosis of osteochondritis dissecans (OCD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22937?source=related_link\">",
"      Elbow injuries in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28455?source=related_link\">",
"      Traumatic causes of acute knee pain and injury in the young athlete",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_36_19015="Leflunomide: Drug information";
var content_f18_36_19015=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Leflunomide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/42/24229?source=see_link\">",
"    see \"Leflunomide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F187136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Arava&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F187137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Leflunomide&reg;;",
"     </li>",
"     <li>",
"      Arava&reg;;",
"     </li>",
"     <li>",
"      Mylan-Leflunomide;",
"     </li>",
"     <li>",
"      Novo-Leflunomide;",
"     </li>",
"     <li>",
"      PHL-Leflunomide;",
"     </li>",
"     <li>",
"      PMS-Leflunomide;",
"     </li>",
"     <li>",
"      Sandoz-Leflunomide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F187163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antirheumatic, Disease Modifying",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F187140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Rheumatoid arthritis:",
"     </b>",
"     Oral: Loading dose: 100 mg/day for 3 days, followed by 20 mg/day;",
"     <b>",
"      Note:",
"     </b>",
"     The loading dose may be omitted in patients at increased risk of hepatic or hematologic toxicity (eg, recent concomitant methotrexate).  Dosage may be decreased to 10 mg/day in patients who have difficulty tolerating the 20 mg dose. Due to the long half-life of the active metabolite, serum concentrations may require a prolonged period to decline after dosage reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      CMV disease, resistant to standard antivirals (unlabeled use):",
"     </b>",
"     Oral: Some authors recommend 100-200 mg/day for 5-7 days, followed by 40-60 mg/day (Avery, 2004; Avery, 2010). Others have utilized the standard rheumatoid arthritis dosing (John, 2004). Adjust dose based on serum concentrations of metabolite and adverse events (Avery, 2008; Avery, 2010; Williams, 2002).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F187141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F187142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No specific dosage adjustment is recommended. There is no clinical experience in the use of leflunomide in patients with renal impairment. The free fraction of M1 is doubled in dialysis patients. Patients should be monitored closely for adverse effects requiring dosage adjustment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F187143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended for use in patients with pre-existing liver disease or in patients with significant hepatic impairment (ALT &gt;2 times ULN). Patients should have LFTs monitored closely.  Discontinue leflunomide if ALT &gt;3 times ULN.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F187164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     ALT elevations &gt;3 times ULN: Discontinue leflunomide and initiate cholestyramine to enhance elimination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Drug elimination procedure: To achieve nondetectable serum concentrations (&lt;0.02 mg/L) of the active metabolite (M1) of leflunomide administer the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cholestyramine: 8 g administered 3 times/day for 11 days. The 11 days do not need to be consecutive unless plasma concentrations need to be lowered rapidly. Verify serum concentrations by 2 separate tests &ge;14 days apart. If plasma concentrations are still high, additional cholestyramine treatment may be considered. In healthy volunteers, cholestyramine 8 g administered 3 times/day for 24 hours decreased M1 concentrations by 40% in 24 hours and 49% to 65% in 48 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Activated charcoal: 50 g every 6 hours for 24 hours was shown to decrease plasma concentrations of M1 by 37% in 24 hours and 48% in 48 hours.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F187114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 10 mg, 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Arava&reg;: 10 mg, 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F187099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9525956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer without regard to meals.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F187115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of active rheumatoid arthritis; indicated to reduce signs and symptoms, and to inhibit structural damage and improve physical function",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F786455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of cytomegalovirus (CMV) disease in transplant recipients resistant to standard antivirals; prevention of acute and chronic rejection in recipients of solid organ transplants",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F16330214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Leflunomide may be confused with lenalidomide",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F187161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Respiratory tract infection (4% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (10%), chest pain (2%), edema (peripheral), palpitation, tachycardia, varicose vein, vasculitis, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (7%), dizziness (4%), pain (2%), anxiety, depression, fever, insomnia, malaise, migraine, sleep disorder, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (10%), rash (10%), pruritus (4%), dry skin (2%), eczema (2%), acne, bruising, dermatitis, hair discoloration, hematoma, nail disorder, skin disorder/discoloration, skin ulcer, subcutaneous nodule",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia (1%), diabetes mellitus, hyperglycemia, hyperlipidemia, hyperthyroidism, menstrual disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (9%), abdominal pain (5% to 6%), dyspepsia (5%), weight loss (4%), anorexia (3%), gastroenteritis (3%), mouth ulceration (3%), vomiting (3%), candidiasis (oral), colitis, constipation, esophagitis, flatulence, gastritis, gingivitis, melena, salivary gland enlarged, stomatitis, taste disturbance, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (5%), albuminuria, cystitis, dysuria, prostate disorder, urinary frequency, vaginal candidiasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Abnormal LFTs (5%), cholelithiasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Abscess",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (5%), joint disorder (4%), tenosynovitis (3%), weakness (3%), paresthesia (2%), synovitis (2%), arthralgia (1%), leg cramps (1%), arthrosis, bone necrosis, bone pain, bursitis, CPK increased, myalgia, neck pain, neuralgia, neuritis, pelvic pain, tendon rupture",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision, cataract, conjunctivitis, eye disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis (7%), cough (3%), pharyngitis (3%), pneumonia (2%), rhinitis (2%), sinusitis (2%), asthma, dyspnea, epistaxis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Accidental injury (5%), allergic reactions (2%), flu-like syndrome (2%), cyst, diaphoresis, hernia, herpes infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, anaphylaxis, angioedema, cholestasis, cutaneous lupus erythematosus, cutaneous necrotizing vasculitis, eosinophilia, erythema multiforme, hepatitis, hepatotoxicity (rare, including hepatic necrosis and hepatic failure, some fatalities reported), interstitial lung disease, jaundice, leukopenia, neutropenia, opportunistic infection, pancreatitis, pancytopenia, peripheral neuropathy, pneumonitis (interstitial), psoriasis exacerbation, pulmonary fibrosis, pustular psoriasis, sepsis, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F187118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to leflunomide or any component of the formulation; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F187103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic reactions: Rare cases of dermatologic reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis) have been reported; discontinue if evidence of severe dermatologic reaction occurs, and begin drug elimination procedures (eg, cholestyramine, activated charcoal).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Use has been associated with rare reports of hepatotoxicity, hepatic failure, and death. Treatment should not be initiated in patients with pre-existing acute or chronic liver disease or ALT &gt;2 x ULN. Use caution in patients with concurrent exposure to potentially hepatotoxic drugs. Monitor ALT levels during therapy; discontinue if ALT &gt;3 x ULN occurs and, if hepatotoxicity is likely leflunomide-induced, start drug elimination procedures",
"     </b>",
"     (eg, cholestyramine, activated charcoal).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infections: May increase susceptibility to infection, including opportunistic pathogens. Severe infections, sepsis, and fatalities have been reported. Not recommended in patients with severe immunodeficiency, bone marrow dysplasia, or severe, uncontrolled infections. Caution should be exercised when considering the use in patients with a history of new/recurrent infections, with conditions that predispose them to infections, or with chronic, latent, or localized infections. Patients who develop a new infection while undergoing treatment should be monitored closely; consider discontinuation of therapy and drug elimination procedures (eg, cholestyramine, activated charcoal) if infection is serious.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Interstitial lung disease: Use has been associated (rarely) with interstitial lung disease; discontinue in patients who develop new onset or worsening of pulmonary symptoms. Drug elimination procedures (eg, cholestyramine, activated charcoal) should be considered if interstitial lung disease occurs; fatal outcomes have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malignancy: Use may affect defenses against malignancies; impact on the development and course of malignancies is not fully defined. As compared to the general population, an increased risk of lymphoma has been noted in clinical trials; however, rheumatoid arthritis has been previously associated with an increased rate of lymphoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral neuropathy: Cases of peripheral neuropathy have been reported; use with caution in patients &gt;60 years of age, receiving concomitant neurotoxic medications or patients with diabetes; discontinue if evidence of peripheral neuropathy occurs and begin drug elimination procedures (eg, cholestyramine, activated charcoal).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic disorders: Use with caution in patients with a prior history of significant hematologic abnormalities; avoid use with bone marrow dysplasia. Use has been associated with rare pancytopenia, agranulocytosis, and thrombocytopenia, generally when given concurrently or recently with methotrexate or other immunosuppressive agents. Monitoring of hematologic function is required; discontinue if evidence of bone marrow suppression and begin drug elimination procedures (eg, cholestyramine, activated charcoal).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tuberculosis: Safety has not been established in patients with latent tuberculosis infection. Patients should be screened for tuberculosis and if necessary, treated prior to initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppressants: If coadministered with other potential immunosuppressive agents, increased monitoring for hematological adverse effects is necessary. If coadministered with methotrexate, increased monitoring for liver toxicity is also necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Women of childbearing potential:",
"     <b>",
"      [U.S. Boxed Warning]: Women of childbearing potential should not receive therapy until pregnancy has been excluded,",
"     </b>",
"     they have  been counseled concerning fetal risk and reliable contraceptive measures have been confirmed. Women of childbearing potential should also undergo drug elimination procedures (eg, cholestyramine, activated charcoal) following discontinuation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug elimination procedure: Due to variations in clearance, it may take up to 2 years to reach low levels of leflunomide metabolite serum concentrations. A drug elimination procedure using cholestyramine or activated charcoal is recommended when a more rapid elimination is needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. Live vaccines should not be given concurrently; there is no data available concerning secondary transmission of live vaccines in patients receiving therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F187157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F187108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease serum concentrations of the active metabolite(s) of Leflunomide. Management: Unless using this combination to intentionally enhance leflunomide elimination, consider an alternative to the bile acid sequestrants when possible.  Separating drug administration is not likely to be effective at avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Charcoal, Activated: May decrease serum concentrations of the active metabolite(s) of Leflunomide. Management: Unless using this combination to intentionally enhance leflunomide elimination, consider an alternative to charcoal when possible.  Separating drug administration is not likely to be effective at avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: May enhance the adverse/toxic effect of Leflunomide. Particular concerns are an increased risk of pancytopenia and/or hepatotoxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May increase serum concentrations of the active metabolite(s) of Leflunomide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teriflunomide: Leflunomide may enhance the adverse/toxic effect of Teriflunomide. Leflunomide may increase the serum concentration of Teriflunomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TOLBUTamide: Leflunomide may increase the serum concentration of TOLBUTamide. Specifically, the active metabolite of leflunomide (M1) may both increase total tolbutamide concentrations and increase the free fraction (i.e., non-protein bound) of tolbutamide. TOLBUTamide may increase the serum concentration of Leflunomide. Specifically, tolbutamide may increase the proportion of non-protein-bound (i.e., free fraction) M1, which is the active metabolite of leflunomide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Leflunomide may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Leflunomide may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F187132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: No interactions with food have been noted. Management: Maintain adequate hydration, unless instructed to restrict fluid intake.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Echinacea may diminish the therapeutic effect of leflunomide.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F187110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F187121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Has been associated with teratogenic and embryolethal effects in animal models at low doses. Leflunomide is contraindicated in pregnant women or women of childbearing potential who are not using reliable contraception. Pregnancy must be excluded prior to initiating treatment.",
"     <b>",
"      [U.S. Boxed Warning]: Women of childbearing potential should not receive therapy until pregnancy has been excluded,",
"     </b>",
"     they have been counseled concerning fetal risk, and reliable contraceptive measures have been confirmed. Following treatment, pregnancy should be avoided until undetectable serum concentrations (&lt;0.02 mg/L) are verified. This may be accomplished by the use of an enhanced drug elimination procedure using cholestyramine. Serum concentrations &lt;0.02 mg/L should be verified by two separate tests performed at least 14 days apart. If serum concentrations are &gt;0.02 mg/L, additional cholestyramine treatment should be considered. Pregnant women exposed to leflunomide should be registered with the pregnancy registry (877-311-8972). It is not known if males taking leflunomide may contribute to fetal toxicity. Males taking leflunomide who wish to father a child should consider discontinuing therapy and using the cholestyramine procedure to eliminate the medication.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F187146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F187122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known whether leflunomide is secreted in human milk. Because the potential for serious adverse reactions exists in the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F187123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F187120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Arava Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $1030.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (30): $1030.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Leflunomide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $492.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (30): $492.44",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F187112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A complete blood count (WBC, platelet count, hemoglobin or hematocrit), serum phosphate, as well as serum transaminase determinations should be monitored at baseline and monthly during the initial 6 months of treatment; if stable, monitoring frequency may be decreased to every 6-8 weeks thereafter (continue monthly when used in combination with other immunosuppressive agents). ALT should be monitored at least monthly for the first 6 months of treatment, then every 6-8 weeks thereafter (discontinue if ALT &gt;3 x ULN, treat with cholestyramine, and monitor liver function at least weekly until normal). In addition, monitor for signs/symptoms of severe infection, abnormalities in hepatic function tests, symptoms of hepatotoxicity, and blood pressure. If coadministered with methotrexate, monthly transaminases (ALT, AST) and serum albumin levels are recommended. Screen for tuberculosis and pregnancy prior to therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     When used for CMV disease, monitor serum trough concentrations of active metabolite (also see Reference Range).",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F11394964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CMV disease:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Timing of serum samples: Initial: Obtain 24 hours after last dose of loading regimen and periodically thereafter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Therapeutic concentration: Active metabolite (A77 1726, M1, or teriflunomide): Trough: 50-80 mcg/mL (Avery, 2010) or up to 100 mcg/mL (Williams, 2002)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F187124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Airuohua (CL);",
"     </li>",
"     <li>",
"      Arabloc (AU, NZ);",
"     </li>",
"     <li>",
"      Arava (AR, AT, AU, BB, BD, BE, BG, BO, BR, BS, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, FI, FR, GB, GR, GT, HK, HN, ID, IE, IL, IN, IT, JM, JP, KP, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PR, PT, PY, RU, SE, SG, SK, SV, TH, TR, TT, TW, UY, VE);",
"     </li>",
"     <li>",
"      Arheuma (TW);",
"     </li>",
"     <li>",
"      R-A (KP);",
"     </li>",
"     <li>",
"      Rheumide (KP);",
"     </li>",
"     <li>",
"      Youtong (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F187102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Leflunomide is an immunodulatory agent that inhibits pyrimidine synthesis, resulting in antiproliferative and anti-inflammatory effects. Leflunomide is a prodrug; the active metabolite is responsible for activity. For CMV, may interfere with virion assembly.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F187117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : M1: 0.13 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: M1: &gt;99% to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to an active metabolite M1 (also known as A77 1726 or teriflunomide), which accounts for nearly all pharmacologic activity; further metabolism to multiple inactive metabolites; undergoes enterohepatic recirculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 80% (relative to oral solution)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: M1: Mean: 14-15 days; enterohepatic recycling appears to contribute to the long half-life of this agent, since activated charcoal and cholestyramine substantially reduce plasma half-life",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: M1: 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (48%); urine (43%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Avery RK, Bolwell BJ, Yen-Lieberman B, et al, &ldquo;Use of Leflunomide in an Allogenic Bone Marrow Transplant Recipient With Refractory Cytomegalovirus Infection,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2004, 34(12):1071-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Avery RK, Mossad SB, Poggio E, et al, &ldquo;Utility of Leflunomide in the Treatment of Complex Cytomegalovirus Syndromes,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 2010, 90(4):419-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/36/19015/abstract-text/20683281/pubmed\" id=\"20683281\" target=\"_blank\">",
"        20683281",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Avery RK, &ldquo;Update in Management of Ganciclovir-Resistant Cytomegalovirus Infection,&rdquo;",
"      <i>",
"       Curr Opin Infect Dis",
"      </i>",
"      , 2008, 21(4):433-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/36/19015/abstract-text/18594298/pubmed\" id=\"18594298\" target=\"_blank\">",
"        18594298",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fox RI, &ldquo;Mechanism of Action of Leflunomide in Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       J Rheumatol",
"      </i>",
"      , 1998, 53:20-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      John GT, Manivannan J, Chandy S, et al, &ldquo;Leflunomide Therapy for Cytomegalovirus Disease in Renal Allograft Recipients,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 2004, 77(9):1460-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/36/19015/abstract-text/15167608/pubmed\" id=\"15167608\" target=\"_blank\">",
"        15167608",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;New Drugs for Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1998, 40(1040):110-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/36/19015/abstract-text/9844625/pubmed\" id=\"9844625\" target=\"_blank\">",
"        9844625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Popovic M, Stefanovic D, Pejnovic N, et al, &ldquo;Comparative Study of the Clinical Efficacy of Four DMARDs (Leflunomide, Methotrexate, Cyclosporine, and Levamisole) in Patients With Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Transplant Proc",
"      </i>",
"      , 1998, 30(8):4135-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/36/19015/abstract-text/9865325/pubmed\" id=\"9865325\" target=\"_blank\">",
"        9865325",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rozman B, &ldquo;Clinical Experience With Leflunomide in Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       J Rheumatol",
"      </i>",
"      , 1998, 53:27-32.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh JA, Furst DE, Bharat A, et al, &ldquo;2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(5):625-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/36/19015/abstract-text/22473917/pubmed\" id=\"22473917\" target=\"_blank\">",
"        22473917",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smolen JS, Kalden JR, Scott DL, et al, &ldquo;Efficacy and Safety of Leflunomide Compared With Placebo and Sulfasalazine in Active Rheumatoid Arthritis: A Double-Blind, Ramdomised, Multicentre Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1999, 353(9149):259-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/36/19015/abstract-text/9929017/pubmed\" id=\"9929017\" target=\"_blank\">",
"        9929017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Williams JW, Mital D, Chong A, et al, \"Experiences With Leflunomide in Solid Organ Transplantation,\"",
"      <i>",
"       Transplantation",
"      </i>",
"      , 2002, 73(3):358-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/36/19015/abstract-text/11884931/pubmed\" id=\"11884931\" target=\"_blank\">",
"        11884931",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10097 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-EA571C30FB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_36_19015=[""].join("\n");
var outline_f18_36_19015=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709008\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187136\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187137\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187163\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187140\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187141\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187142\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187143\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187164\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187114\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187099\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9525956\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187115\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786455\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16330214\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187161\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187118\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187103\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187157\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187108\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187132\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187110\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187121\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187146\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187122\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187123\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187120\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187112\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11394964\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187124\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187102\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187117\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10097\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10097|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/42/24229?source=related_link\">",
"      Leflunomide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_36_19016="Angiokeratomas";
var content_f18_36_19016=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F81624%7ENEPH%2F71039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F81624%7ENEPH%2F71039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Angiokeratomas are distributed in a typical symmetrical fashion on the torso",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cho ME, Kopp JB. Fabry disease in the era of enzyme replacement therapy: a renal perspective. Pediatr Nephrol 2004; 19:583. Copyright &copy; 2004 Springer Science and Business Media.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Higher power view demonstrates the elevated papules",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cho ME, Kopp JB. Fabry disease in the era of enzyme replacement therapy: a renal perspective. Pediatr Nephrol 2004; 19:583. Copyright &copy; 2004 Springer Science and Business Media.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_36_19016=[""].join("\n");
var outline_f18_36_19016=null;
var title_f18_36_19017="Chemoprevention in oral dysplasia and head and neck cancer";
var content_f18_36_19017=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chemoprevention in oral dysplasia and head and neck cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/36/19017/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/36/19017/contributors\">",
"     Charles M Rudin, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/36/19017/contributors\">",
"     Shanthi Marur, MD, MBBS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/36/19017/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/36/19017/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/36/19017/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/36/19017/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/36/19017/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/36/19017/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in the understanding of the biology of head and neck squamous cell cancer have resulted in the development of two important concepts that provide the rationale for pharmacologic chemoprevention in patients at risk for the development of invasive cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34825?source=see_link\">",
"     \"Head and neck squamous cell carcinogenesis: Molecular and genetic alterations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=see_link\">",
"     \"Epidemiology and risk factors for head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Field cancerization &mdash; Patients with head and neck cancer have a global cancer predilection throughout the oropharyngeal mucosa.",
"     </li>",
"     <li>",
"      Multistep carcinogenesis &mdash; These malignancies result from a multistep carcinogenesis pathway with defined intermediate stages, leading to fully transformed, invasive, and metastatic cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although standard treatment options for oral dysplasia range from watchful waiting to laser surgery and aggressive resection, none of these approaches is of clear clinical benefit.",
"   </p>",
"   <p>",
"    Methods for decreasing the incidence of invasive tumor growth in patients with recognizable premalignant lesions have fallen into two general categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoidance of further known carcinogenic exposures (eg, tobacco and alcohol) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/3\">",
"       3",
"      </a>",
"      ]. This strategy, while clearly important, is not always sufficient since many or most of the critical genetic alterations leading to transformation have already occurred in \"early\" premalignant lesions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34825?source=see_link\">",
"       \"Head and neck squamous cell carcinogenesis: Molecular and genetic alterations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chemoprevention or pharmacologic intervention to reverse or inhibit carcinogenic progression [",
"      <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/4\">",
"       4",
"      </a>",
"      ]. Chemoprevention can be considered in two categories: primary chemoprevention is directed at individuals with de novo premalignant lesions, while secondary chemoprevention is directed at cancer patients who have undergone potentially curative therapy, in order to prevent recurrent disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FIELD CARCINOGENESIS AND CHEMOPREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept of field carcinogenesis was initially proposed in the 1950s [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/5\">",
"     5",
"    </a>",
"    ]. Subsequent studies have confirmed that patients with cancer or premalignant dysplastic lesions in the oropharyngeal mucosa are at significant risk for the development of head and neck cancer at distant mucosal sites [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In the absence of such a field defect, recognition and surgical removal of evident premalignant disease might comprise a more rational and curative approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=see_link\">",
"     \"Pathology of head and neck neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The field defect has been attributed to carcinogenic exposure from multiple risk factors, including tobacco, alcohol, and viral infection, throughout the entire oropharyngeal mucosa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=see_link\">",
"     \"Epidemiology and risk factors for head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple directly mutagenic substances, including benzo[a]pyrene and nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) are found at significant levels in tobacco smoke, and are readily diffusible [",
"      <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ethanol is a synergistic carcinogen in smokers, markedly increasing the incidence of head and neck squamous cell cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. Ethanol may act by enhancing the uptake of potent tobacco carcinogens by epithelial cells. Alternatively, it may function as a tumor promoter through tissue damage and resultant chronic regenerative proliferation, overwhelming the repair capacity of the cell for the ongoing genetic damage introduced by tobacco mutagens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Like tobacco, ethanol is distributed over large areas of the oropharyngeal mucosa, leading to potential transforming events at multiple sites. Thus in patients with premalignant lesions the entire exposed mucosa, the \"field,\" has a strong predilection for carcinogenic progression.",
"   </p>",
"   <p>",
"    The model of field carcinogenesis is supported by both epidemiologic and molecular studies. As an example, cancer at one site in the head and neck is a strong predictor for the development of a second primary tumor elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Second tumors can either occur at or close to the same time as the primary lesion (synchronous) or at least six months later (metachronous). Synchronous second tumors are most often occult lesions in the head and neck, whereas metachronous second tumors most often involve the head and neck, lung, and esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of the diagnosis and staging of head and neck cancer\", section on 'Incidence of second and multiple primaries'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Molecular analysis has shown that first and second lesions are frequently clonally distinct, ruling out locoregional recurrence as a universal explanation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/14\">",
"     14",
"    </a>",
"    ]. In contrast, other studies have found that physically distinct mucosal tumors may share a common origin, suggesting that genetically abnormal precursor cells have the capacity to migrate extensively within the mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Consistent with this finding is the observation that histologically normal mucosa in patients with head and neck cancer contains evidence of genetically abnormal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/17\">",
"     17",
"    </a>",
"    ]. This may in large part explain the failure of surgical excision of grossly evident dysplastic lesions to substantially reduce the risk of cancer in patients with premalignant lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INTERMEDIATE MARKERS IN CHEMOPREVENTION STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The endpoint of decreased incidence of cancer requires very large numbers of patients followed over long periods of time. As a result, there has been interest in defining alternative surrogate endpoints to both evaluate the efficacy of chemopreventive therapies, and to serve as molecular prognostic factors for risk stratification in chemoprevention trials.",
"   </p>",
"   <p>",
"    The accurate identification of lesions with carcinogenic potential is clearly critical to such studies. Grossly evident lesions that may be precancerous include leukoplakia (white plaques) and erythroplakia (red plaques); however, these terms may include mucosal abnormalities with little or no cancer risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=see_link\">",
"     \"Pathology of head and neck neoplasms\"",
"    </a>",
"    .) In addition, standard histologic assessment alone lacks adequate specificity and sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/18\">",
"     18",
"    </a>",
"    ]. Histologic criteria in noninvasive dysplastic lesions that have been suggested to correlate with progressive carcinogenic potential include the degree of nuclear atypia, failure of organized differentiation, loss of cell-cell contacts, the presence of keratotic bodies, and the cellular DNA content.",
"   </p>",
"   <p>",
"    Genetic definitions of progressive premalignant stages are beginning to be defined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34825?source=see_link\">",
"     \"Head and neck squamous cell carcinogenesis: Molecular and genetic alterations\"",
"    </a>",
"    .) Histologic progression has been correlated with sequential clonal genomic alterations, including deletions of chromosome arms 3p, 9p, 11q and 17p [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. A number of tumor suppressor genes thought to be critical in tumorigenesis have been mapped within these regions.",
"   </p>",
"   <p>",
"    Many of these genomic alterations have in turn been associated with abnormal expression of a number of proteins that may hold promise as potential intermediate endpoints and molecular prognostic factors for chemoprevention studies. The reversal of molecular alterations that are tightly linked to the development of oral cancer (eg, epidermal growth factor receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/22\">",
"     22",
"    </a>",
"    ], transforming growth factor-alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/23\">",
"     23",
"    </a>",
"    ], p53 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/24-26\">",
"     24-26",
"    </a>",
"    ], proliferating cell nuclear antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/27\">",
"     27",
"    </a>",
"    ], telomerase [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/28\">",
"     28",
"    </a>",
"    ], and retinoic acid receptor-beta [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/29\">",
"     29",
"    </a>",
"    ]) might indicate a reduced risk of oral cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=see_link\">",
"     \"Epidemiology and risk factors for head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, at least some data suggest that expression of podoplanin, a lymphatic endothelial marker whose biologic roles are incompletely understood, might be one of the most powerful predictive factors for oral cancer development in patients with leukoplakia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/30\">",
"     30",
"    </a>",
"    ]. These data were derived from a randomized chemoprevention trial comparing 13-cis-retinoic acid versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    plus retinyl palmitate versus retinyl palmitate alone in 163 patients with oral leukoplakia. High levels of podoplanin expression by immunohistochemistry were associated with a significantly higher incidence of oral cancer (5-year risk 37 versus 8 percent in those with podoplanin-negative lesions). Risk could be further stratified by combining histology (the presence of absence of dysplasia) with podoplanin expression.",
"   </p>",
"   <p>",
"    It remains unclear which of these factors may be the most useful predictors of carcinogenic progression, and which molecular abnormalities, when normalized, best predict reduction in subsequent cancer risk. It should also be noted that a complete histologic response in premalignant lesions may be seen following administration of a chemopreventive agent in patients despite the persistence of chromosomal abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CHEMOPREVENTION TRIALS FOR UPPER AERODIGESTIVE TRACT DYSPLASIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most published chemoprevention trials for premalignant lesions of the oral cavity and oropharynx are based on use of either naturally occurring compounds (vitamin A, vitamin E,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    ) or synthetically derived retinoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Vitamin A, vitamin E, and beta-carotene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports on the utility of vitamin A for the treatment of oral leukoplakia date back to 1957, when a remarkable 90 percent response rate was described in 20 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/31\">",
"     31",
"    </a>",
"    ]. Although this high response rate could not be duplicated, subsequent trials have confirmed the activity of vitamin A for oral leukoplakia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. However, the confirmatory trials focused on tobacco and betel nut chewers in a population likely to be deficient in vitamin A. Thus, the applicability of these results to disease in relatively developed nations (where vitamin deficiency is rare) is unclear.",
"   </p>",
"   <p>",
"    High response rates have also been described with the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    , a precursor of vitamin A, to patients with oral leukoplakia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. In one series of 24 patients, for example, there were 15 partial and two complete responses with no significant toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One double-blind placebo-controlled trial has been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/37\">",
"     37",
"    </a>",
"    ]. This study randomized 160 fishermen and women in India with oral precancerous lesions to vitamin A (300,00 IU per week), carotene (360 mg per week), or placebo over a 12 month period. The complete regression rates were 10 percent with placebo, 52 percent with vitamin A, and 33 percent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    . No major toxicities were observed. One-half of the responders to beta-carotene and two-thirds of those to vitamin A relapsed after the supplements were discontinued.",
"   </p>",
"   <p>",
"    In addition to the above studies in patients with premalignant lesions,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    , alpha tocopherol (vitamin E), vitamin A, and N-acetylcysteine have been evaluated for primary prevention in patients at risk for head and neck cancer, and for secondary prevention in patients with head and neck cancer (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/38-42\">",
"     38-42",
"    </a>",
"    ]. No evidence of benefit has been noted, while a possible detrimental effect of supplementation with beta-carotene plus alpha-tocopherol was suggested in a secondary prevention trial in which 540 patients undergoing radiation therapy for stage I or II head and neck cancer were randomly assigned to both agents or placebo for three years, starting the day of radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/41\">",
"     41",
"    </a>",
"    ]. Beta-carotene supplementation was discontinued after 156 patients were enrolled because of ethical concerns. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link&amp;anchor=H23#H23\">",
"     \"Cigarette smoking and other risk factors for lung cancer\", section on 'Dietary factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After a median follow-up of 52 months, supplemented patients had a significantly higher rate of tumor recurrence or second primary cancer (hazard ratio [HR] 1.86, 95% CI 1.27 to 2.72) during the supplementation period, which decreased thereafter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Synthetic retinoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most extensively studied compounds for premalignant oropharyngeal disease are the synthetic retinoids [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/43\">",
"     43",
"    </a>",
"    ]. The first clinical analyses of these agents were reported in 1978 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. These studies examined the utility of three retinoids: 13-cis-retinoic acid, all-trans-retinoic acid, and etretinate; all were active with overall response rates of 59 to 92 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175757862\">",
"    <span class=\"h3\">",
"     Primary chemoprevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;These initial observations provided the rationale for a pivotal randomized, placebo-controlled study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    (13-cis-retinoic acid, 1 to 2",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in 44 patients with leukoplakia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/46\">",
"     46",
"    </a>",
"    ]. This was the first trial to include pretreatment and posttreatment histologic evaluation in all patients, permitting analysis of the response among truly dysplastic lesions. After three months of therapy, both the overall clinical response rates (67 versus 10 percent) and the response rates among patients with biopsy-proved dysplasia (54 versus 10 percent) were significantly higher in the actively treated patients.",
"   </p>",
"   <p>",
"    There were, however, two negative results in this study: toxicity and relapse. Toxicity was particularly severe in patients dosed at the higher dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day), with 47 percent of patients requiring dose reduction. Patients at the lower dose level (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) had less toxicity and did not require dose reduction, although most noted xeroderma and 29 percent developed conjunctivitis.",
"   </p>",
"   <p>",
"    After completion of therapy, over 50 percent of responders relapsed within three months. This observation prompted a second trial in which 70 patients with leukoplakia underwent induction with high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    (1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for three months) and were then randomized to \"maintenance\" with low dose isotretinoin (0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for nine months) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/47\">",
"     47",
"    </a>",
"    ]. Of the 53 patients who could be evaluated, a response to maintenance therapy or continuation of stable lesions was significantly more common with isotretinoin (92 versus 45 percent, P&lt;0.001). Side effects were generally mild, but more prominent with isotretinoin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Secondary chemoprevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinoid therapy has also been evaluated as a secondary chemopreventive after surgery or radiation for localized head and neck cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/39-41,48-51\">",
"     39-41,48-51",
"    </a>",
"    ]. Only one trial, using relatively high doses, has suggested benefit from this approach. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    (50 to 100",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per day for 12 months) did not appear to impact either locoregional or distant relapse rates compared to placebo, it did produce a significant reduction in the incidence of second primary tumors, mostly head and neck, esophagus, and lung (4 versus 24 percent with maintenance placebo at 32 months). It is notable that the incidence of second primaries in the control arm of this trial was higher than reported in other series. In addition, significant toxicity was again seen with retinoid therapy, resulting in a high dropout rate on the treatment arm.",
"   </p>",
"   <p>",
"    In contrast to these results, three other placebo-controlled randomized trials (one of which is published only in abstract form [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/49\">",
"     49",
"    </a>",
"    ]) have failed to demonstrate any benefit from lower doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. The largest of the three trials conducted by the Radiation Therapy Oncology Group (RTOG) involved 1190 patients with treated stage I or II head and neck cancer who were randomly assigned to isotretinoin 30 mg daily or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/50\">",
"     50",
"    </a>",
"    ]. Isotretinoin provided no significant benefit in terms of time to develop a second primary tumors, rate of second primary tumors, overall survival, or recurrence-free survival.",
"   </p>",
"   <p>",
"    The mechanism by which retinoids affect premalignant lesions has not been fully elucidated. Many premalignant dysplastic lesions (60 percent in one series compared to none in normal specimens) express very low levels of the nuclear retinoid receptor beta (RAR beta), a component of several bipartite transcription factors responsive to retinoic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/52\">",
"     52",
"    </a>",
"    ]. This deficiency is reversed with retinoid therapy, which may reestablish many aspects of normal growth and differentiation in the aberrantly proliferating premalignant clone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. In one study of patients with premalignant lesions, the highest response rate (70 percent) was noted in patients with low baseline expression of the tumor suppressor p53 protein and upregulation of RAR beta mRNA after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/53\">",
"     53",
"    </a>",
"    ]. Retinoids also have antiangiogenic activity that may directly or indirectly contribute to their antineoplastic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Targeted therapy using ONYX-015",
"    </span>",
"    &nbsp;&mdash;&nbsp;A promising molecular target for chemoprevention is the p53 tumor suppressor gene, which is inactivated in approximately 40 to 50 percent of head and neck squamous cell cancers and in up to 45 percent of dysplastic mucosal lesions of the head and neck [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. ONYX-015 is an adenovirus containing a deleted E1B 55-kDa gene, which selectively replicates in, and lyses p53-deficient cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/52/26441?source=see_link\">",
"     \"Adenovirus pathogenesis and vector applications\"",
"    </a>",
"    .) Intratumoral administration of ONYX-015 is well tolerated and has shown biologic activity in patients with recurrent squamous cell head and neck cancer.",
"   </p>",
"   <p>",
"    The safety and efficacy of topical application of ONYX-015 as a chemopreventive agent was studied in 22 patients with oral dysplasia who received a mouthwash formulation held in the mouth for 30 minutes in one of three different schedules: daily for five days every four weeks, once weekly, or daily for five days, followed by weekly treatment for five weeks, repeated in six week blocks [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/26\">",
"     26",
"    </a>",
"    ]. Biopsy of oral mucosal lesions was performed prior to treatment initiation, and after three, six, or 12 months of therapy, depending upon the treatment schedule. Treatment was well-tolerated, and histologic resolution of dysplasia was seen in seven of 19 assessable patients. The grade of dysplasia improved in one additional patient. This therapy remains investigational and long-term benefit has not been assessed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Targeted therapy using EGFR inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another promising pharmacologic chemoprevention target is the epidermal growth factor receptor (EGFR), which is dysregulated in the majority of premalignant and malignant oral lesions. The addition of the anti-EGFR monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    to radiation therapy (RT) was associated with a significant improvement in survival relative to RT alone in patients with locally advanced HNSCC [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/55\">",
"     55",
"    </a>",
"    ]. In this setting, as well as in patients with metastatic disease, cetuximab is well tolerated with a low toxicity profile [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34825?source=see_link&amp;anchor=H5#H5\">",
"     \"Head and neck squamous cell carcinogenesis: Molecular and genetic alterations\", section on 'EGFR and transforming growth factor-alpha'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40345?source=see_link\">",
"     \"Treatment of metastatic and recurrent head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A prospective, randomized, multicenter, phase II trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    has completed enrollment of and includes 19 patients with high-risk, premalignant upper aerodigestive lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/57\">",
"     57",
"    </a>",
"    ]. Patients at high risk for malignant progression were grouped as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unresectable or diffuse high-grade dysplasia;",
"     </li>",
"     <li>",
"      Prior, successfully treated head and neck cancer with persistent or recurrent high-grade dysplasia;",
"     </li>",
"     <li>",
"      Low-grade or high-grade leukoplakic lesions with loss of heterozygosity (LOH) at 3p or 9p21.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients were randomized to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    <span class=\"nowrap\">",
"     400mg/m2",
"    </span>",
"    IV on week one followed by",
"    <span class=\"nowrap\">",
"     250mg/m2",
"    </span>",
"    weekly for seven weeks versus observation with the option for crossover to cetuximab for patients originally randomized to the observation arm. Histologic grade (1 = benign, 2 = mild dysplasia, 3 = moderate dysplasia, 4 = severe",
"    <span class=\"nowrap\">",
"     dysplasia/carcinoma",
"    </span>",
"    in situ, 5 = invasive cancer) and change in grade of dysplasia was evaluated. The primary endpoint is histologic response and secondary endpoints are response based on clinical assessment by direct visualization of the lesion, development of oral cancer and exploratory correlative studies to evaluate EGFR pathway in pre-and post-treatment biopsies. The final results will be available in 2013 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     NSAID therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intake of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and other nonsteroidal antiinflammatory drugs (NSAIDs) prevents the development of intraepithelial neoplasia in the colon and rectum. The mechanism of this chemopreventive effect is thought to be inhibition of COX-2 and diminished synthesis of prostaglandins, which are overproduced in colorectal tumors and have been implicated in tumorigenesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=see_link\">",
"     \"NSAIDs (including aspirin): Role in prevention of cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A similar rationale has been applied to the study of NSAIDs as chemopreventive agents for head and neck cancer, since both premalignant and malignant lesions of the oral cavity overexpress COX-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. In addition, administration of NSAIDs to laboratory animals prevents oral cancer development [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials are not available, and the results of case control and cohort studies are conflicting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case-control study reporting a protective effect of NSAID intake on the risk of head and neck cancer in tobacco users [",
"      <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/62\">",
"       62",
"      </a>",
"      ] was later retracted because of concerns over data fabrication [",
"      <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A possible protective effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      use on the development of head and neck cancer was suggested in a questionnaire-based case control study of 529 head and neck cancer patients and 529 hospital-based controls matched for age, sex and smoking status [",
"      <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/64\">",
"       64",
"      </a>",
"      ]. Compared to never users, aspirin use was associated with a significant 25 percent reduction in the risk of head and neck cancer, and there was a trend toward greater risk reduction with increasing duration of use. When analyzed by smoking and alcohol exposure levels, participants exposed to heavy smoking and alcohol use did not appear to benefit from the protective effect of aspirin.",
"     </li>",
"     <li>",
"      A population-based cohort study from Denmark failed to find evidence that NSAIDs protect against oral cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/65\">",
"       65",
"      </a>",
"      ]. However, the study did not control for tobacco or alcohol use, and considered only prescription use of NSAIDs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Long-term ingestion of NSAIDs may be limited by toxicity. A novel approach, topical application, was used in a double-blind trial in which 57 patients with oropharyngeal leukoplakia were randomly assigned (in a 2:1 ratio) to a 30 second, twice daily rinse with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    (0.1 percent solution) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/66\">",
"     66",
"    </a>",
"    ]. Compared to controls, the treated group did not have a greater objective decrease in the size of the leukoplakia lesions (which were bidimensionally measured at days 0 and 90), or in their histologic appearance.",
"   </p>",
"   <p>",
"    Since surrogate markers of exposure in the oral cavity (eg, prostaglandin E2 inhibition) were not studied, it is difficult to ascertain whether this negative result reflects ineffective delivery of the chemopreventive agent to the oral epithelial cells, or an incorrect hypothesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other compounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;An array of natural compounds such as green tea extract, curcumin analogs, pomegranate juice, and soybeans are under investigation in head and neck chemoprevention trials. These compounds contain high levels of polyphenols which have antioxidant properties and inhibit carcinogenesis mediated by downstream signaling pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/67-69\">",
"     67-69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral cancer occurs in a region of the body that is generally accessible to physical examination. Thus, head and neck cancer has great potential for prevention through dissemination of anti-tobacco health education information and routine mouth examinations in high-risk individuals to detect premalignant or early malignant lesions. Screening initiatives have been undertaken in industrialized and developing countries.",
"   </p>",
"   <p>",
"    The challenge with conducting screening studies are in identifying the high-risk group, the appropriate intervention or screening test, the duration of screening initiative, and the health outcome of interest. The quality of a screening program is affected by participation rate, test performance (sensitivity and specificity), frequency of screening, participant compliance, and duration of follow up of positive test results.",
"   </p>",
"   <p>",
"    In studies involving over 250,000 subjects in Sri Lanka, primary health care workers detected a total of 44 new oral cancers. However, mortality was not reduced in these areas, possibly due to poor compliance following initial screening [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In Cuba, the Oral Cancer Case Finding Program (OCCFP) was based upon health education and thorough examination of the oral cavity by \"stomatologists\" in specialized stomatology centers [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/71\">",
"     71",
"    </a>",
"    ]. Between 1983 and 1990, over 10 million patients were examined, 30,478 were referred for detected abnormalities, and 8259 complied with their referral. In the last group, 2367 leukoplakias, 853 other precancerous lesions, and 708 malignant neoplasms were diagnosed. The potential efficacy of this program is evident by an increased incidence of stage I oral cancers (from 22 to 48 percent) and the reduced incidence of more advanced (stages II to IV) cancers (from 77 to 52 percent). However, these health outcome measures are subject to the potential influences of both \"length bias\" and \"lead time bias\". A reduction in population mortality would be a more appropriate surrogate measure of the effectiveness of the screening method.",
"   </p>",
"   <p>",
"    Investigators in the United States have also studied the effectiveness of screening programs. In one study, screening for squamous cell carcinomas of the oral cavity, pharynx, and larynx with symptom assessment and systematic inspection of the oral mucosa was performed by primary care practitioners at health care sites serving inner-city residents of Boston [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/72\">",
"     72",
"    </a>",
"    ]. Of the 4611 tobacco users older than 40 years who were screened, 313 had specific criteria for otolaryngologic referral. The prevalence of oral mucosal lesions and persistent hoarseness was 13 percent and 11 percent respectively. Abnormal findings were seen in over 70 percent of referred patients and cancer was diagnosed in 3 percent.",
"   </p>",
"   <p>",
"    An impact of screening on reduced mortality from oral cancer was suggested in a trial from India in which seven population clusters (municipal administrative units) were randomly assigned to three rounds of oral visual inspection by trained health workers at three-year intervals, and six were assigned to a control group, receiving standard care [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/73\">",
"     73",
"    </a>",
"    ]. Eligibility was open to healthy patients over the age of 35. Screen-positive patients were subsequently referred for clinical examination, biopsy and treatment. In the intervention group, there were 205 cases of oral cancer, and 77 oral cancer deaths; in the control group the values were 158 cases and 87 deaths, respectively, but the difference in mortality was not statistically significant (mortality rate ratio 0.79, 95% CI 0.51 to 1.22). Notably, only 3218 of the 5145 individuals who screened positive complied with referral. Among users of alcohol, tobacco, or both, there was a significant 33 percent reduction in the risk of oral cancer death (mortality rate ratio 0.66). The authors concluded from these findings that the use of oral visual screening in high risk groups of tobacco",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    alcohol users was potentially capable of preventing at least 37,000 oral cancer deaths worldwide.",
"   </p>",
"   <p>",
"    These data demonstrate that a primary-care screening strategy for head and neck cancer can reach a large number of at risk individuals and that early detection and treatment can reduce overall mortality. Whether or not any of these strategies are cost-effective is not known. Currently, there is no effective oral cancer screening program, although screening high risk individuals in developing countries could be an effective prevention strategy.",
"   </p>",
"   <p>",
"    Future screening strategies based upon detection of molecular abnormalities (eg, promoter hypermethylation) in body fluids such as serum and saliva may hold some promise, but this technology is not yet ready for clinical use [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/74-77\">",
"     74-77",
"    </a>",
"    ]. A breakthrough in head and neck cancer has been identifying HPV-16 as a risk factor for the development of oropharyngeal cancer in patients with minimal exposure to alcohol and tobacco. The group at risk for infection with HPV-16 are individuals who have had multiple sexual partners, high lifetime number of vaginal-sex partners, high lifetime number of oral-sex partners, and marijuana use [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recent developments in chemoprevention have triggered renewed interest in preventive (as opposed to therapeutic) approaches to cancer. These include demonstration of the impact of retinoid compounds on premalignant lesions of the oral cavity and oropharynx, as well as preclinical, early clinical, and epidemiologic evidence of the potential effectiveness of NSAIDs and \"molecular therapies\" (ONYX-015, anti-EGFR agents). Disappointingly however, the largest studies of retinoids as chemopreventative agents have been negative.",
"   </p>",
"   <p>",
"    To date, there is no uniformly accepted effective treatment to prevent malignant transformation of leukoplakia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19017/abstract/80\">",
"     80",
"    </a>",
"    ]. The strong predictive power of podoplanin analysis, particularly in conjunction with histology, may help to guide future therapeutic trials in this field by focusing therapy on those patients at highest risk of progression to invasive cancer.",
"   </p>",
"   <p>",
"    Molecular carcinogenesis models of upper aerodigestive tract malignancy have generated a number of new potential targets for intervention in cancer progression. A second generation of chemopreventive strategies based upon known genetic defects in premalignant disease is only now being investigated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34825?source=see_link\">",
"     \"Head and neck squamous cell carcinogenesis: Molecular and genetic alterations\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/1\">",
"      Geyer C, Papadimitrakopoulou V, Hong WK. Chemoprevention in head and neck cancer: basic science and clinical application. Semin Radiat Oncol 1998; 8:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/2\">",
"      Sidransky D. Molecular genetics of head and neck cancer. Curr Opin Oncol 1995; 7:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/3\">",
"      Schantz SP, Ostroff JS. Novel approaches to the prevention of head and neck cancer. Proc Soc Exp Biol Med 1997; 216:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/4\">",
"      Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997; 278:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/5\">",
"      SLAUGHTER DP, SOUTHWICK HW, SMEJKAL W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/6\">",
"      Partridge M, Pateromichelakis S, Phillips E, et al. A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res 2000; 60:3893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/7\">",
"      Lee JJ, Hong WK, Hittelman WN, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000; 6:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/8\">",
"      Gupta PC, Murti PR, Bhonsle RB. Epidemiology of cancer by tobacco products and the significance of TSNA. Crit Rev Toxicol 1996; 26:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/9\">",
"      Lewin F, Norell SE, Johansson H, et al. Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: a population-based case-referent study in Sweden. Cancer 1998; 82:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/10\">",
"      Murata M, Takayama K, Choi BC, Pak AW. A nested case-control study on alcohol drinking, tobacco smoking, and cancer. Cancer Detect Prev 1996; 20:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/11\">",
"      Cooper JS, Pajak TF, Rubin P, et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 1989; 17:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/12\">",
"      Licciardello JT, Spitz MR, Hong WK. Multiple primary cancer in patients with cancer of the head and neck: second cancer of the head and neck, esophagus, and lung. Int J Radiat Oncol Biol Phys 1989; 17:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/13\">",
"      Jones AS, Morar P, Phillips DE, et al. Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer 1995; 75:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/14\">",
"      Chung KY, Mukhopadhyay T, Kim J, et al. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res 1993; 53:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/15\">",
"      Bedi GC, Westra WH, Gabrielson E, et al. Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res 1996; 56:2484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/16\">",
"      Partridge M, Pateromichelakis S, Phillips E, et al. Profiling clonality and progression in multiple premalignant and malignant oral lesions identifies a subgroup of cases with a distinct presentation of squamous cell carcinoma. Clin Cancer Res 2001; 7:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/17\">",
"      Nees M, Homann N, Discher H, et al. Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumors. Cancer Res 1993; 53:4189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/18\">",
"      Mao L, El-Naggar AK, Papadimitrakopoulou V, et al. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst 1998; 90:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/19\">",
"      Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996; 56:2488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/20\">",
"      Rosin MP, Cheng X, Poh C, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 2000; 6:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/21\">",
"      Mao L, Lee JS, Fan YH, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996; 2:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/22\">",
"      Shin DM, Ro JY, Hong WK, Hittelman WN. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994; 54:3153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/23\">",
"      Rubin Grandis J, Tweardy DJ, Melhem MF. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res 1998; 4:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/24\">",
"      Shin DM, Kim J, Ro JY, et al. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994; 54:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/25\">",
"      Koch WM, Brennan JA, Zahurak M, et al. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996; 88:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/26\">",
"      Rudin CM, Cohen EE, Papadimitrakopoulou VA, et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 2003; 21:4546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/27\">",
"      Shin DM, Voravud N, Ro JY, et al. Sequential increases in proliferating cell nuclear antigen expression in head and neck tumorigenesis: a potential biomarker. J Natl Cancer Inst 1993; 85:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/28\">",
"      Mutirangura A, Supiyaphun P, Trirekapan S, et al. Telomerase activity in oral leukoplakia and head and neck squamous cell carcinoma. Cancer Res 1996; 56:3530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/29\">",
"      Xu XC, Ro JY, Lee JS, et al. Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res 1994; 54:3580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/30\">",
"      Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, et al. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 2008; 26:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/31\">",
"      Wolf K. Zur vitamin A behandlung der leukoplakien. Arch Klin Exp Dermatol 1957; :206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/32\">",
"      Stich HF, Rosin MP, Hornby AP, et al. Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with beta-carotene and with beta-carotene plus vitamin A. Int J Cancer 1988; 42:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/33\">",
"      Stich HF, Hornby AP, Mathew B, et al. Response of oral leukoplakias to the administration of vitamin A. Cancer Lett 1988; 40:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/34\">",
"      Garewal HS, Meyskens FL Jr, Killen D, et al. Response of oral leukoplakia to beta-carotene. J Clin Oncol 1990; 8:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/35\">",
"      Garewal H. Chemoprevention of oral cancer: beta-carotene and vitamin E in leukoplakia. Eur J Cancer Prev 1994; 3:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/36\">",
"      Toma S, Benso S, Albanese E, et al. Treatment of oral leukoplakia with beta-carotene. Oncology 1992; 49:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/37\">",
"      Sankaranarayanan R, Mathew B, Varghese C, et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncol 1997; 33:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/38\">",
"      Liede K, Hietanen J, Saxen L, et al. Long-term supplementation with alpha-tocopherol and beta-carotene and prevalence of oral mucosal lesions in smokers. Oral Dis 1998; 4:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/39\">",
"      Jyothirmayi R, Ramadas K, Varghese C, et al. Efficacy of vitamin A in the prevention of loco-regional recurrence and second primaries in head and neck cancer. Eur J Cancer B Oral Oncol 1996; 32B:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/40\">",
"      van Zandwijk N, Dalesio O, Pastorino U, et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 2000; 92:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/41\">",
"      Bairati I, Meyer F, G&eacute;linas M, et al. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst 2005; 97:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/42\">",
"      Wright ME, Virtamo J, Hartman AM, et al. Effects of alpha-tocopherol and beta-carotene supplementation on upper aerodigestive tract cancers in a large, randomized controlled trial. Cancer 2007; 109:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/43\">",
"      Khuri FR, Lippman SM, Spitz MR, et al. Molecular epidemiology and retinoid chemoprevention of head and neck cancer. J Natl Cancer Inst 1997; 89:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/44\">",
"      Koch HF. Biochemical treatment of precancerous oral lesions: the effectiveness of various analogues of retinoic acid. J Maxillofac Surg 1978; 6:59.",
"     </a>",
"    </li>",
"    <li>",
"     Effect of retinoids on precancerous lesions of oral mucosa. In: Retinoids: Advances in Basic Research and Therapy, Spring-Verlag, Berlin 1981. p.273.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/46\">",
"      Hong WK, Endicott J, Itri LM, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986; 315:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/47\">",
"      Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 1993; 328:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/48\">",
"      Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990; 323:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/49\">",
"      Pinto, H, Li, Y, Loprinzi, C, et al. Phase III trial of low-dose 13-cis retinoic acid for prevention of second primary cancers in stage I-II head and neck cancer - an Eastern Cooperative Oncology Group study (abstract). Proc Am Soc Clin Oncol 2001; 20:222a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/50\">",
"      Khuri FR, Lee JJ, Lippman SM, et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 2006; 98:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/51\">",
"      Perry CF, Stevens M, Rabie I, et al. Chemoprevention of head and neck cancer with retinoids: a negative result. Arch Otolaryngol Head Neck Surg 2005; 131:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/52\">",
"      Lotan R, Xu XC, Lippman SM, et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 1995; 332:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/53\">",
"      Shin DM, Xu XC, Lippman SM, et al. Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemoprevention. Clin Cancer Res 1997; 3:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/54\">",
"      Lingen MW, Polverini PJ, Bouck NP. Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma. Cancer Res 1998; 58:5551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/55\">",
"      Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/56\">",
"      Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23:8646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/57\">",
"      Phase II Study of Single-Agent Cetuximab for Treatment of High-Risk Pre-malignant Upper Aerodigestive Lesions. J Clin Oncol 2008; 12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/58\">",
"      Soriano AF, Helfrich B, Chan DC, et al. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 1999; 59:6178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/59\">",
"      Renkonen J, Wolff H, Paavonen T. Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions. Virchows Arch 2002; 440:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/60\">",
"      Wang Z, Fuentes CF, Shapshay SM. Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell. Laryngoscope 2002; 112:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/61\">",
"      Shiotani H, Denda A, Yamamoto K, et al. Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res 2001; 61:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/62\">",
"      Sudb&oslash; J, Lee JJ, Lippman SM, et al. Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study. Lancet 2005; 366:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/63\">",
"      Curfman GD, Morrissey S, Drazen JM. Retraction: Sudb&oslash; J et al. DNA content as a prognostic marker in patients with oral leukoplakia. N Engl J Med 2001;344:1270-8 and Sudb&oslash; J et al. The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med 2004;350:1405-13. N Engl J Med 2006; 355:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/64\">",
"      Jayaprakash V, Rigual NR, Moysich KB, et al. Chemoprevention of head and neck cancer with aspirin: a case-control study. Arch Otolaryngol Head Neck Surg 2006; 132:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/65\">",
"      Friis S, Poulsen A, Pedersen L, et al. Use of nonsteroidal anti-inflammatory drugs and risk of oral cancer: a cohort study. Br J Cancer 2006; 95:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/66\">",
"      Mulshine JL, Atkinson JC, Greer RO, et al. Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res 2004; 10:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/67\">",
"      Schwartz JL, Baker V, Larios E, Chung FL. Molecular and cellular effects of green tea on oral cells of smokers: a pilot study. Mol Nutr Food Res 2005; 49:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/68\">",
"      Seeram NP, Adams LS, Henning SM, et al. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem 2005; 16:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/69\">",
"      Armstrong WB, Kennedy AR, Wan XS, et al. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 2000; 6:4684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/70\">",
"      Sankaranarayanan R. Health care auxiliaries in the detection and prevention of oral cancer. Oral Oncol 1997; 33:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/71\">",
"      Santana JC, Delgado L, Miranda J, S&aacute;nchez M. Oral Cancer Case Finding Program (OCCFP). Oral Oncol 1997; 33:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/72\">",
"      Prout MN, Sidari JN, Witzburg RA, et al. Head and neck cancer screening among 4611 tobacco users older than forty years. Otolaryngol Head Neck Surg 1997; 116:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/73\">",
"      Sankaranarayanan R, Ramadas K, Thomas G, et al. Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet 2005; 365:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/74\">",
"      Carvalho AL, Jeronimo C, Kim MM, et al. Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res 2008; 14:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/75\">",
"      Nunes DN, Kowalski LP, Simpson AJ. Detection of oral and oropharyngeal cancer by microsatellite analysis in mouth washes and lesion brushings. Oral Oncol 2000; 36:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/76\">",
"      El-Naggar AK, Mao L, Staerkel G, et al. Genetic heterogeneity in saliva from patients with oral squamous carcinomas: implications in molecular diagnosis and screening. J Mol Diagn 2001; 3:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/77\">",
"      Wadsworth JT, Somers KD, Stack BC Jr, et al. Identification of patients with head and neck cancer using serum protein profiles. Arch Otolaryngol Head Neck Surg 2004; 130:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/78\">",
"      Vidal L, Gillison ML. Human papillomavirus in HNSCC: recognition of a distinct disease type. Hematol Oncol Clin North Am 2008; 22:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/79\">",
"      Zhao M, Rosenbaum E, Carvalho AL, et al. Feasibility of quantitative PCR-based saliva rinse screening of HPV for head and neck cancer. Int J Cancer 2005; 117:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19017/abstract/80\">",
"      Lodi G, Sardella A, Bez C, et al. Interventions for treating oral leukoplakia. Cochrane Database Syst Rev 2001; :CD001829.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3391 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-E93FDBD5C8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_36_19017=[""].join("\n");
var outline_f18_36_19017=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FIELD CARCINOGENESIS AND CHEMOPREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INTERMEDIATE MARKERS IN CHEMOPREVENTION STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CHEMOPREVENTION TRIALS FOR UPPER AERODIGESTIVE TRACT DYSPLASIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Vitamin A, vitamin E, and beta-carotene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Synthetic retinoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H175757862\">",
"      - Primary chemoprevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Secondary chemoprevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Targeted therapy using ONYX-015",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Targeted therapy using EGFR inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      NSAID therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other compounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/52/26441?source=related_link\">",
"      Adenovirus pathogenesis and vector applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=related_link\">",
"      Cigarette smoking and other risk factors for lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=related_link\">",
"      Epidemiology and risk factors for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34825?source=related_link\">",
"      Head and neck squamous cell carcinogenesis: Molecular and genetic alterations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=related_link\">",
"      Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=related_link\">",
"      NSAIDs (including aspirin): Role in prevention of cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=related_link\">",
"      Overview of the diagnosis and staging of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=related_link\">",
"      Pathology of head and neck neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40345?source=related_link\">",
"      Treatment of metastatic and recurrent head and neck cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_36_19018="Diagnostic approach to abdominal pain in adults";
var content_f18_36_19018=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic approach to abdominal pain in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/36/19018/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/36/19018/contributors\">",
"     Robert M Penner, BSc, MD, FRCPC, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/36/19018/contributors\">",
"     Sumit R Majumdar, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/36/19018/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/36/19018/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/36/19018/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/36/19018/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/36/19018/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal pain can be a challenging complaint for both primary care and specialist physicians because it is frequently a benign complaint, but it can also herald serious acute pathology. Abdominal pain is present on questioning of 75 percent of otherwise healthy adolescent students [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/1\">",
"     1",
"    </a>",
"    ] and in about half of all adults [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/2\">",
"     2",
"    </a>",
"    ]. The prevalence of abdominal pain is consistently high across diverse geographic regions and age groups, and it is frequently a result of the irritable bowel syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    From the large population of patients with benign causes of abdominal pain, clinicians are responsible for trying to determine which patients can be safely observed or treated symptomatically and which require further investigation or specialist referral. This task is complicated by the fact that abdominal pain is often a nonspecific complaint that presents with other symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, the overall sensitivity and specificity of the history and physical examination in diagnosing the different causes of abdominal pain is poor [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/7\">",
"     7",
"    </a>",
"    ], particularly for benign conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Fortunately, studies of the accuracy of history and physical examination for the more serious causes of abdominal pain (eg, acute appendicitis), alone or in combination with focused investigations, have yielded better results [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews an approach to the triage and diagnosis of adults with acute or chronic nontraumatic abdominal pain. A more complete differential diagnosis of abdominal pain and its pathophysiology is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=see_link\">",
"     \"Differential diagnosis of abdominal pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TRIAGE AND DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute abdominal pain frequently requires urgent investigation and management. Some patients may require assessment of their airway, breathing, and circulation, followed by appropriate resuscitation. Many patients will require analgesics, which can be administered judiciously without compromising physical assessment of peritoneal signs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/13-19\">",
"     13-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with suspected surgical abdomens must be transferred to an acute care facility where urgent surgical consultation and management are available. Patients requiring resuscitation or parenteral analgesia should also be transferred to an acute care facility where more appropriate nursing care and laboratory and radiology facilities are available. Patients with less acute illnesses may require consultation or referral for further management following a more detailed history and initial assessment, as described below.",
"   </p>",
"   <p>",
"    Once the patient is stable, or while stability is being achieved, the differential diagnosis can be considered in terms of \"symptom clusters\" in order to guide further management and investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should first be asked about the time course of pain, both as part of the evaluation for a surgical abdomen and because once a surgical abdomen has been excluded the remainder of the evaluation will be guided by the chronicity of the symptoms along with the location of pain.",
"   </p>",
"   <p>",
"    The history should include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Location of pain",
"     </li>",
"     <li>",
"      Radiation of pain",
"     </li>",
"     <li>",
"      Factors that exacerbate or improve symptoms such as food, antacids, exertion, defecation",
"     </li>",
"     <li>",
"      Associated symptoms including fevers, chills, weight loss or gain, nausea, vomiting, diarrhea, constipation, hematochezia, melena, jaundice, change in the color of urine or stool, change in the diameter of stool",
"     </li>",
"     <li>",
"      Past medical and surgical history, including risk factors for cardiovascular disease and details of previous abdominal surgeries",
"     </li>",
"     <li>",
"      Family history of bowel disorders",
"     </li>",
"     <li>",
"      Alcohol intake",
"     </li>",
"     <li>",
"      Intake of medications including over the counter medications such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , and NSAIDs",
"     </li>",
"     <li>",
"      Menstrual and contraceptive history in women",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more detailed review of the history in a patient with abdominal pain is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40323?source=see_link&amp;anchor=H2#H2\">",
"     \"History and physical examination in adults with abdominal pain\", section on 'History'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination will vary depending upon the location and chronicity of the patient's symptoms. However, a typical examination will include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Measurement of blood pressure, pulse, and temperature",
"     </li>",
"     <li>",
"      Examination of the eyes and skin for jaundice",
"     </li>",
"     <li>",
"      Auscultation and percussion of the chest",
"     </li>",
"     <li>",
"      Auscultation of the abdomen for bowel sounds",
"     </li>",
"     <li>",
"      Palpation of the abdomen for masses, tenderness, and peritoneal signs (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Peritonitis'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Rectal examination including testing of stool for occult blood",
"     </li>",
"     <li>",
"      Pelvic examination in women with lower abdominal pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more detailed review of the physical examination in a patient with abdominal pain is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40323?source=see_link&amp;anchor=H3#H3\">",
"     \"History and physical examination in adults with abdominal pain\", section on 'Physical Examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ACUTE VERSUS CHRONIC PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;While an arbitrary interval, such as 12 weeks, can be used to separate acute from chronic abdominal pain, there is no strict time period that will classify the differential diagnosis unfailingly. A clinical judgment must be made that considers whether this is an accelerating process, one that has reached a plateau, or one that is longstanding but intermittent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain of less than a few days duration that has worsened progressively until the time of presentation is clearly \"acute.\"",
"     </li>",
"     <li>",
"      Pain that has remained unchanged for months or years can be safely classified as chronic.",
"     </li>",
"     <li>",
"      Pain that does not clearly fit either category might be called subacute and requires consideration of the differential diagnoses for both acute and chronic pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pain in a sick or unstable patient should generally be managed as acute, since patients with chronic abdominal pain may present with an acute exacerbation of a chronic problem or a new and unrelated problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ACUTE ABDOMINAL PAIN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Surgical abdomen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first diagnoses that must be considered in patients with acute abdominal pain are those that may require urgent surgical intervention. The 'surgical abdomen' can be usefully defined as a condition with a rapidly worsening prognosis in the absence of surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/20\">",
"     20",
"    </a>",
"    ]. Two syndromes that constitute urgent surgical referrals are obstruction and peritonitis. The latter encompasses most severe abdominal pathology since intraperitoneal hemorrhage or viscus perforation typically present with common features of peritonitis.",
"   </p>",
"   <p>",
"    Patients with acute surgical abdomens will often have a rapid symptom evolution, but patients who have evolved from partial to complete bowel obstruction may present with weeks of vague abdominal pain, followed by a sudden deterioration. Pain is typically severe in all of these conditions, and it can be associated with unstable vital signs, fever, and dehydration.",
"   </p>",
"   <p>",
"    Location and evolution of symptoms are helpful in narrowing the differential diagnosis, as in the classic evolution from visceral and periumbilical pain, to sharp right lower quadrant pain, in acute appendicitis (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31370?source=see_link\">",
"     \"Acute appendicitis in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    ). A particularly high level of suspicion should be maintained for severe pathology in immunosuppressed patients (including those taking immunosuppressive agents or having comorbidities affecting immune function, such as diabetes or renal failure) and the elderly, where classic signs of peritoneal inflammation may be attenuated.",
"   </p>",
"   <p>",
"    Only after the clinician is satisfied that the abdominal presentation is not an acute surgical emergency can consideration of other diagnostic possibilities begin. Patients should not eat or drink while a diagnosis of a surgical abdomen remains under consideration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstruction generally presents as pain together with anorexia, bloating, nausea, vomiting (which may be bilious or feculent depending on the level of obstruction), and obstipation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=see_link\">",
"     \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical examination may reveal distension and high-pitched or absent bowel sounds. Abdominal percussion reveals tympany from proximally dilated loops of bowel. An abdominal mass, if present, may suggest an etiology for the obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with peritonitis of any cause tend to \"look sick\" and lie still to minimize their discomfort. They may receive little benefit from analgesics. Although rebound tenderness and its variants are classically thought to reflect peritonitis, abdominal wall rigidity and tenderness elicitable by percussion or very light palpation are also often overlooked features consistent with a surgical abdomen. Other subtle signs of peritonitis that can be pursued include diminished bowel sounds and pain worsened when an examiner lightly bumps the stretcher.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Initial diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a surgical abdomen should have the following laboratory measurements:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count with differential",
"     </li>",
"     <li>",
"      Electrolytes, BUN, creatinine, and glucose",
"     </li>",
"     <li>",
"      Aminotransferases, alkaline phosphatase, and bilirubin",
"     </li>",
"     <li>",
"      Lipase",
"     </li>",
"     <li>",
"      Urinalysis",
"     </li>",
"     <li>",
"      Pregnancy test in women of childbearing potential",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the presence of fever or unstable vital signs, blood and urine cultures should be performed.",
"   </p>",
"   <p>",
"    While these laboratory tests are important, they are not sufficient to rule in or rule out a diagnosis of surgical abdomen, as a surgical abdomen is a clinical diagnosis.",
"   </p>",
"   <p>",
"    Abdominal radiographs (including a plain radiograph and an upright or lateral decubitus radiograph) are a crucial step in decision making for the suspected surgical abdomen, as proximally dilated loops of bowel are the hallmark of intestinal obstruction, and free intraperitoneal air can confirm a suspicion of hollow organ perforation. Peritonitis in the absence of perforation or obstruction may not yield any conclusive radiographic findings. Where CT scanning is immediately available and necessary for further evaluation, as described below, abdominal plain films are not necessary, as they do not provide additional information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Subsequent diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients clearly in need of urgent surgical intervention may proceed directly to the operating room for diagnosis and management, and some patients will need no further preoperative assessment because of a clear history consistent with surgical disease such as appendicitis.",
"   </p>",
"   <p>",
"    Many patients will not have a firm diagnosis after initial assessment, and in these cases, careful observation of the patient's course will be the most important factor in their management, since severe pathology typically becomes more obvious with time, and benign conditions may spontaneously improve. In addition to watchful waiting (which we consider to be an important diagnostic test), the following additional investigations can also be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the case of suspected partial or complete intestinal obstruction, a CT scan of the abdomen is more sensitive and more likely to yield a diagnosis than plain abdominal radiographs (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=see_link\">",
"       \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/21\">",
"       21",
"      </a>",
"      ]. All",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      studies should be avoided in patients with suspected obstruction because they may result in retention of barium and interference with subsequent diagnostic tests. Intestinal pseudoobstruction should be suspected when signs and symptoms of obstruction are present, but distended bowel on radiography extends to the rectum. In these patients, a water-soluble contrast enema can safely rule out mechanical obstruction and potentially have a therapeutic effect [",
"      <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/50/22311?source=see_link\">",
"       \"Acute colonic pseudo-obstruction (Ogilvie's syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When clinical signs of peritonitis are present, but the etiology is not clear, an abdominal ultrasound is the test of choice, since it can effectively assess for appendicitis and abdominal abscess and obtains adequate views of intrapelvic pathology [",
"      <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abdominal CT scan may be helpful as an alternative to ultrasound or in the clarification of equivocal ultrasound findings. In pregnant women with abdominal pain, ultrasound should be performed because it is not associated with radiation exposure or contrast, and pregnant patients may present with atypical history and physical findings of common pathologies [",
"      <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In some patients, surgical intervention should be considered even before confirmatory testing. Patients with a painful pulsatile abdominal mass, with or without bruit, should be suspected to have a ruptured aortic aneurysm. In unstable patients with suspected aneurysm rupture, surgical referral should not be delayed. In stable patients, abdominal ultrasound is the preferred investigation, although CT scanning is also acceptable. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link\">",
"       \"Clinical features and diagnosis of abdominal aortic aneurysm\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link\">",
"       \"Management of asymptomatic abdominal aortic aneurysm\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients presenting with less alarming symptoms, early laparoscopy has been considered as a potential cost-effective diagnostic and therapeutic strategy, when initial testing has not identified an etiology. In one randomized study of early laparoscopy and appendectomy for acute nonspecific abdominal pain in women, however, there was no difference in recurrence of abdominal pain over a 30 month follow-up period when women who had early laparoscopy were compared with control patients who received treatment based on findings from in-hospital observation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Right upper quadrant pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain involving the liver or biliary tree is generally located in the right upper quadrant, but it may radiate to the back or epigastrium. Because hepatic pain only results when the capsule of the liver is \"stretched,\" most pain in the right upper quadrant is related to the biliary tree. Viral or drug-induced hepatitis can sometimes cause acute right upper quadrant pain as well.",
"   </p>",
"   <p>",
"    Initial assessment of patients with right upper quadrant pain must consider serious causes and complications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of fever and jaundice in a patient with right upper quadrant pain leads to a clinical diagnosis of ascending cholangitis, necessitating appropriate resuscitation, broad spectrum antibiotic therapy, and referral for consideration of invasive tests and treatments (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=see_link\">",
"       \"Acute cholangitis\"",
"      </a>",
"      ). Mild bilirubin elevations may not be appreciable clinically, so this diagnosis needs to be revisited if subsequent lab studies indicate an elevated bilirubin.",
"     </li>",
"     <li>",
"      Acute cholecystitis can also present as a systemically unwell patient with low-grade fever. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonabdominal etiologies of upper abdominal pain must be considered. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Nonabdominal etiologies of upper abdominal pain'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once these possibilities have been considered, the history can be explored in more detail. Since gallstones are such a common cause of relatively benign pain, as well as the serious complications mentioned above, the history for right upper quadrant pain focuses initially on risk factors for gallstone disease and previous episodes of similar pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4489?source=see_link\">",
"     \"Epidemiology of and risk factors for gallstones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=see_link\">",
"     \"Uncomplicated gallstone disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Initial diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with acute right upper quadrant pain should have the following laboratory measurements:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count with differential",
"     </li>",
"     <li>",
"      Electrolytes, BUN, creatinine, and glucose",
"     </li>",
"     <li>",
"      Aminotransferases, alkaline phosphatase, and bilirubin",
"     </li>",
"     <li>",
"      Lipase",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Plain films of the abdomen are unlikely to yield much information, so abdominal ultrasound is the test of choice for most patients, since its sensitivity for detecting gallstones and ability to measure biliary dilatation exceeds that of CT scanning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21992?source=see_link\">",
"     \"Ultrasonography of the hepatobiliary tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The main limitation of abdominal ultrasound in this setting is that it is often unable to visualize the distal common bile duct, which is hidden behind duodenal air. The diagnosis of distal biliary obstruction is therefore often made by the surrogate marker of ultrasonographic biliary dilatation.",
"   </p>",
"   <p>",
"    Patients with an acute rise in aminotransferases and right upper quadrant pain most likely have choledocholithiasis, particularly if there is also an acute rise in bilirubin. Alkaline phosphatase does not rise for many hours after pain onset. Availability of previous lab work is very helpful in this case, so that chronically elevated enzymes are not mistaken for a component of the acute presentation.",
"   </p>",
"   <p>",
"    Patients with a classic presentation of choledocholithiasis may go directly for endoscopic retrograde cholangiopancreatography (ERCP), but an initial ultrasound may still be helpful in clarifying the diagnosis (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37175?source=see_link\">",
"     \"Endoscopic balloon dilatation for removal of bile duct stones\"",
"    </a>",
"    ). When the right upper quadrant pain is vague, or associated with preceding flu-like illness or risk factors for viral hepatitis, the ultrasound can help by excluding biliary dilatation and revealing the inflamed liver parenchyma of acute hepatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Subsequent diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Where available, endoscopic ultrasound can be performed before the more invasive endoscopic retrograde cholangiopancreatography (ERCP), in order to visualize the distal common bile duct. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43557?source=see_link\">",
"     \"Endoscopic ultrasound in patients with suspected choledocholithiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Magnetic resonance cholangiopancreatography (MRCP) is a noninvasive alternative to ERCP that has adequate sensitivity and might be reasonable when therapeutic intervention is not immediately necessary or in populations where ERCP may be of higher than usual risk [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/26\">",
"     26",
"    </a>",
"    ]. MRCP is also appropriate in patients in whom the biliary tree may be endoscopically inaccessible, such as those who have undergone gastric bypass surgery or any Roux-en-Y surgical procedure,",
"   </p>",
"   <p>",
"    Most cases of ascending cholangitis will require ERCP for both diagnosis and treatment, so patients in whom this diagnosis is considered should be referred to a facility with ERCP capacity as soon as possible after stabilization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=see_link\">",
"     \"Acute cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Epigastric pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epigastric pain that is relatively sudden in onset is suggestive of pancreatitis, particularly when it radiates to the back and is associated with nausea, vomiting, and anorexia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since pancreatitis often occurs as a complication of gallstone disease, a patient with such a presentation should be questioned regarding any past or concurrent history of right upper quadrant pain. The other major risk factors for pancreatitis are alcohol use, trauma, and recent endoscopic retrograde cholangiopancreatography (ERCP). The patient's medications should be reviewed for an etiology of medication-induced pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=see_link\">",
"     \"Etiology of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Epigastric pain that is less acute is challenging to assess in an initial clinical encounter. Evidence suggests that physicians are unable to accurately diagnose specific etiologies of such pain based on history and physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/8,9,27\">",
"     8,9,27",
"    </a>",
"    ]. Once pancreatic and hepatobiliary pain are excluded, pain limited to the epigastrium, which may be associated with bloating, abdominal fullness, heartburn, or nausea can be classified as dyspepsia.",
"   </p>",
"   <p>",
"    Although physicians are typically taught that specific features of dyspepsia indicate its etiology (eg, ulcers improve with eating, positional changes precipitate gastroesophageal reflux), controversy exists as to whether dyspepsia can be usefully categorized based on history alone. Given this, in the evaluation of acute epigastric pain, it is most useful to define which patients with dyspepsia require further investigation and which can safely undergo a therapeutic trial or watchful waiting [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/9,28,29\">",
"     9,28,29",
"    </a>",
"    ]. Alarm features that suggest a need for further investigation include (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=see_link&amp;anchor=H75708801#H75708801\">",
"     \"Approach to the patient with dyspepsia\", section on 'Initial evaluation'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age over 50",
"     </li>",
"     <li>",
"      Weight loss",
"     </li>",
"     <li>",
"      Persistent vomiting",
"     </li>",
"     <li>",
"      Dysphagia",
"     </li>",
"     <li>",
"      Anemia",
"     </li>",
"     <li>",
"      Hematemesis",
"     </li>",
"     <li>",
"      Palpable abdominal mass",
"     </li>",
"     <li>",
"      Family history of upper gastrointestinal carcinoma",
"     </li>",
"     <li>",
"      Previously identified pathology requiring reassessment, or history of gastric surgery for pathology that could recur",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The acuity and severity of the presentation will dictate the urgency of referral.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Nonabdominal etiologies of upper abdominal pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper abdominal pain should always be considered a possible extension of cardiac pain, since myocardial infarction can present with referred pain. Patients should be asked about exertional symptoms or shortness of breath, and patients suspected of having an acute coronary syndrome should be referred for urgent evaluation and management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Upper abdominal pain can also reflect pleural or pulmonary pathology when it arises in the lower thorax. Lower lobe pulmonary pathologies (eg, pneumonia, pulmonary embolism) or inflammatory pleural effusions (eg, empyema, pulmonary infarction) can present with what appears to be abdominal pain because they occur at the threshold of the abdomen. These can generally be excluded with a careful history and physical examination of the chest for percussion dullness, abnormal breath sounds, signs of consolidation, or a pleural rub. Chest radiographs can help exclude many thoracic pathologies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Diagnostic testing for pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a history suggestive of pancreatitis should have the following laboratory measurements:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count with differential",
"     </li>",
"     <li>",
"      Electrolytes, BUN, creatinine, and glucose",
"     </li>",
"     <li>",
"      Aminotransferases, alkaline phosphatase, and bilirubin",
"     </li>",
"     <li>",
"      Lipase (amylase is a less specific alternative, where lipase is not available [",
"      <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/30\">",
"       30",
"      </a>",
"      ])",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Elevation of serum lipase in the presence of epigastric pain is very suggestive of pancreatitis. The differential diagnosis is limited but includes other processes, like malignancy, that involve the pancreas.",
"   </p>",
"   <p>",
"    The initial workup of pancreatitis will usually involve an abdominal ultrasound to exclude gallstones, although CT scanning is more sensitive for the diagnosis of pancreatitis. Patients with chronic pancreatitis may present with exacerbations suggestive of recurrent acute pancreatitis. These patients may not exhibit impressive rises in lipase or amylase, so if risk factors for chronic pancreatitis are present, especially heavy alcohol use, or if the patient has steatorrhea, imaging with CT or ultrasound may play a crucial role in diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A biliary etiology (ie gallstone-related) for pancreatitis should be suspected, even in the absence of ultrasound findings, in patients with elevated transaminases and pancreatitis. These patients should be investigated with ERCP [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/31\">",
"     31",
"    </a>",
"    ]. In equivocal cases, MRCP or endoscopic ultrasound can be considered, as described above. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Subsequent diagnostic testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Diagnostic testing for dyspepsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with dyspepsia and alarm symptoms (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Epigastric pain'",
"    </a>",
"    above) should generally be investigated with gastroscopy. Gastroscopy is preferred to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow for the evaluation of reflux esophagitis, peptic ulcer disease, gastric and esophageal cancer, because of potential for obtaining biopsies and higher sensitivity in some situations (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=see_link\">",
"     \"Approach to the patient with dyspepsia\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. Patients younger than 45 to 50 years without any alarm symptoms can be managed with a therapeutic trial of antisecretory therapy without further investigation. Some experts recommend testing for Helicobacter pylori in such patients. The American Gastroenterological Association (AGA) technical review for the evaluation of dyspepsia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/36\">",
"     36",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     file://www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Patients unresponsive to a therapeutic trial of antisecretory medication, or with alarm symptoms and a negative gastroscopy, might benefit from abdominal ultrasonography and a reassessment of whether they may have pancreatic or biliary pathology with a predominantly epigastric presentation. Repeating transaminases on multiple occasions will help identify patients with intermittent biliary pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12874?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sphincter of Oddi dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Lower abdominal pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain in the lower abdomen can be associated with the distal intestinal tract, but it may also radiate down from upper abdominal structures or up from the pelvis. Features most suggestive of a colonic or ileal source include diarrhea or hematochezia and rectal symptoms such as urgency and tenesmus.",
"   </p>",
"   <p>",
"    Left",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    right lower quadrant pain, when occurring together with diarrhea, are suggestive of colitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ileitis, which may be infectious, ischemic, medication-associated, or due to inflammatory bowel disease. Diverticulitis presents more frequently as left lower quadrant pain than right lower quadrant pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34919?source=see_link\">",
"     \"Clinical manifestations and diagnosis of colonic diverticular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The history should include risk factors for infectious and ischemic causes, any history of NSAID use, and risk factors for inflammatory bowel disease (IBD) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/17/7450?source=see_link\">",
"     \"Definition, epidemiology, and risk factors in inflammatory bowel disease\"",
"    </a>",
"    ). Patients should be asked about, and examined for, extraintestinal manifestations of IBD such as iritis, erythema nodosum, clubbing, aphthous ulcers of the mouth, or perianal disease (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"    </a>",
"    ). Patients should be asked about urinary symptoms such as frequency, urgency, and dysuria.",
"   </p>",
"   <p>",
"    In older patients, a similar presentation to that of IBD, with abdominal pain and a change in bowel habits, can be the first sign of colon cancer. Presentations of colonic neoplasia are highly variable, so risk factors for colon cancer (particularly age and family history) should be considered in patients with lower abdominal pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17946?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Nonabdominal etiologies of lower abdominal pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower abdominal pain can reflect retroperitoneal pathology. Renal colic results in pain that may begin in the flank and migrate through the abdomen to the groin, testes, or labia. Depending on the site of ureteric obstruction, it may mimic an acute abdomen. CT scanning can effectively diagnose kidney stones and guide management (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=see_link\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\"",
"    </a>",
"    ). Cystitis from a urinary tract infection can also produce lower abdominal (particularly suprapubic) pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=see_link\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lower abdominal pain (pelvic pain) in women is frequently caused by disorders of the female reproductive organs. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Lower abdominal pain in women'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory evaluation in a patient with lower abdominal pain should include a complete blood count. Older patients found to have anemia should have iron studies; iron-deficiency anemia in the elderly is highly suspicious for gastrointestinal malignancy. A pregnancy test should be performed in women of childbearing potential, even when pregnancy is felt to be unlikely.",
"   </p>",
"   <p>",
"    Patients with lower abdominal pain associated with diarrhea will often have self-limited presentations and can be managed expectantly, if clear risk factors for infectious diarrhea are present or if their presentation remains mild and limited to less than one week of symptoms. Patients with more severe or persistent presentations, and immunosuppressed patients, should have stool sent for culture for enteric pathogens, microscopy for ova and parasites, and measurement of Clostridium difficile toxin. Patients with illness exceeding two weeks with negative cultures, systemically unwell patients, and immunosuppressed patients, will often require investigation with colonoscopy or flexible sigmoidoscopy to clarify the diagnosis and tailor therapy. Patients presenting with predominantly diarrheal illnesses (rather than prominent abdominal pain) are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32025?source=see_link\">",
"     \"Approach to the adult with acute diarrhea in developed countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ileal pathology may present with acute or subacute diarrhea, right lower quadrant mass or pain, and weight loss or fever. When ileal pathology is suspected, the terminal ileum can be visualized by small bowel follow-through, as well as by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema, but colonoscopy has the advantage of allowing biopsies.",
"   </p>",
"   <p>",
"    Acute left lower quadrant pain with fever and elevated white blood cell count is suggestive of diverticulitis. Diverticulitis can also present as right lower quadrant pain. Patients suspected of having diverticulitis should undergo an abdominal CT scan to assist in diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34919?source=see_link\">",
"     \"Clinical manifestations and diagnosis of colonic diverticular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Lower abdominal pain in women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower abdominal pain in women must be considered as a spectrum with causes of pelvic pain. Additional history should focus on the regularity and timing of menstrual periods, possibility of pregnancy, and presence of vaginal discharge or bleeding. A recent history of dyspareunia or dysmenorrhea is also suggestive of pelvic pathology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43032?source=see_link\">",
"     \"Approach to the woman with sexual pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/60/39879?source=see_link\">",
"     \"Primary dysmenorrhea in adult women: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the causes of lower abdominal pain discussed above (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Lower abdominal pain'",
"    </a>",
"    above), the most common etiologies of acute lower abdominal pain in women include: pelvic inflammatory disease (PID); adnexal cysts or masses with bleeding, torsion, or rupture; ectopic pregnancy; and uterine pain due to infection (endometritis) or due to degeneration, infarction, or torsion of leiomyomas.",
"   </p>",
"   <p>",
"    A pelvic examination is part of the physical examination whenever pelvic pathology is in the differential diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42681?source=see_link\">",
"     \"The gynecologic history and pelvic examination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The size and symmetry of the uterus are determined; symmetrical enlargement suggests intrauterine pregnancy (or adenomyosis), while irregular enlargement is more indicative of leiomyomas, although asymmetric enlargement can also be caused by bowel or adnexal masses adherent to the uterus. The normal uterus is not tender; the presence of uterine pain suggests infection or pathology related to leiomyomas (torsion, degeneration, infarction).",
"     </li>",
"     <li>",
"      The adnexal areas are checked for the presence of appropriately sized, mobile ovaries (eg, about 2 by 3 cm), which are normally mildly tender upon compression. Ovarian masses both enlarge the ovary and make it more globular. Ovarian neoplasms and ectopic pregnancies are generally not painful unless bleeding, ruptured, or torsed, in which case pelvic pain is aggravated by coitus or bimanual examination of the adnexae. A fixed, painful adnexal mass is suggestive of an endometrioma or tuboovarian abscess. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link\">",
"       \"Approach to the patient with an adnexal mass\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=see_link\">",
"       \"Differential diagnosis of the adnexal mass\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Severe pain elicited by cervical movement and palpation of the adnexae suggests pelvic peritonitis from PID. Adnexal masses are not typically present unless there are tuboovarian abscesses or hydrosalpinges.",
"     </li>",
"     <li>",
"      One or more of the following is suggestive of endometriosis: localized tenderness in the cul-de-sac or uterosacral ligaments; palpable tender nodules in the cul-de-sac, uterosacral ligaments, or rectovaginal septum; pain with uterine movement; tender, enlarged adnexal masses; or fixation of adnexa or uterus in a retroverted position. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of endometriosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp;Diagnostic testing &mdash; Women with lower abdominal pain should have the following initial diagnostic tests:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count with differential",
"     </li>",
"     <li>",
"      Quantitative pregnancy test in women of childbearing potential",
"     </li>",
"     <li>",
"      Microscopic exam in saline (wet mount) of any abnormal vaginal discharge",
"     </li>",
"     <li>",
"      Tests for chlamydia and gonococcus in women with risk factors for sexually transmitted infections, mucopurulent cervical discharge, or suspected PID",
"     </li>",
"     <li>",
"      Urinalysis (and urine culture if urinalysis shows leukocytes)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PID should be considered when acute left, right, or bilateral abdominal pain is accompanied by fever and an elevated white blood count with left shift. A purulent cervical discharge may be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infarction or torsion of ovarian cysts and uterine leiomyomas is often accompanied by fever and leukocytosis as well, but usually the elevations are lower than those seen with PID. Abnormal vaginal discharge is typically not observed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link\">",
"     \"Approach to the patient with an adnexal mass\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=see_link\">",
"     \"Differential diagnosis of the adnexal mass\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abdominal pain, menstrual cycle abnormalities (missed or late menstrual period), and vaginal bleeding are the classic symptoms of ectopic pregnancy. Clinical manifestations typically appear six to eight weeks after a missed menstrual period, but they can occur later. A sensitive test for human chorionic gonadotropin will always be positive. However, an intrauterine pregnancy may coexist with any of the causes of abdominal pain described above and give rise to these same findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with a positive pregnancy test and those in whom the diagnosis remains unclear after physical examination and the above tests generally require a pelvic ultrasound examination. Leiomyomas, adnexal masses, and intrauterine pregnancy can generally be visualized on and evaluated by pelvic ultrasound. Fluid in the cul-de-sac is suggestive of a ruptured ovarian cyst or ectopic pregnancy. Sonography is often normal with infection, but it may reveal accumulation of fluid and debris in the uterine cavity or thickened, fluid-filled oviducts with or without free pelvic fluid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Generalized abdominal pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any patient presenting with severe generalized abdominal pain should be aggressively evaluated for a surgical abdomen (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Surgical abdomen'",
"    </a>",
"    above). The evaluation should only proceed once a process requiring acute surgery has been excluded.",
"   </p>",
"   <p>",
"    Among the conditions that may require urgent surgical management, yet present without clear peritoneal findings, is acute mesenteric",
"    <span class=\"nowrap\">",
"     ischemia/mesenteric",
"    </span>",
"    infarction. If clinically reasonable, the diagnosis of mesenteric ischemia should be entertained, particularly if the patient has the classic finding of pain out of proportion to physical findings or risk factors such as congestive heart failure, recent myocardial infarction, hypotension, hypovolemia, sepsis, cardiac surgery, or requirement for dialysis (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44377?source=see_link\">",
"     \"Acute mesenteric ischemia\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. Mesenteric ischemia might also be considered in the differential diagnosis of young persons with a known personal or family history of hypercoagulable state or venous thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Generalized abdominal pain with vomiting",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diarrhea, alone or in association with systemic symptoms, can represent an acute self-limited illness, such as viral or bacterial enteritis or colitis, or toxin-mediated food poisoning. Recently consumed meals that may have been inadequately cooked or improperly stored can offer clues to a source of illness: toxin-mediated illnesses can occur within hours of ingestion, but bacterial colitis generally requires 24 to 48 hours to develop (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24265?source=see_link\">",
"     \"Differential diagnosis of microbial foodborne disease\"",
"    </a>",
"    ). Multisystem symptoms, such as upper respiratory tract involvement or myalgias, may suggest a viral etiology. A history of family members or other contacts developing a similar illness is valuable, not only because it points towards a likely diagnosis, but because the patient's illness is likely to mimic the course of their contact's. Depending on their degree of systemic illness, patients with self-limited symptoms may need only reassurance or may require significant supportive care.",
"   </p>",
"   <p>",
"    Diffuse abdominal pain can also be a nonspecific symptom of underlying metabolic disease. The presence of systemic illness, fatigue, weakness, nausea, flu-like symptoms, or signs and symptoms of endocrinopathies that are associated with abdominal pain should signal a search for metabolic abnormalities. Many of these conditions are fairly indolent or undiagnosed until triggered by an acute precipitant, such as infection, dehydration, surgical stress, or alcohol or drug use. Examples include diabetic ketoacidosis and Addison's disease. The abdominal pain will typically be diffuse and nonprogressive, without focal tenderness or other peritoneal features. It may be associated with unstable vital signs or fever, depending on its underlying cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with symptoms suggestive of an acute infectious gastroenteritis or toxin-mediated food poisoning, the most useful diagnostic tool will often be watchful waiting for spontaneous recovery.",
"   </p>",
"   <p>",
"    Patients in whom a metabolic etiology of abdominal pain is suspected should have the following laboratory measurements:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Electrolytes, with calculation of an anion gap",
"     </li>",
"     <li>",
"      BUN, creatinine, blood glucose",
"     </li>",
"     <li>",
"      Calcium",
"     </li>",
"     <li>",
"      Complete blood count with differential",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further investigation for metabolic causes beyond initial lab work is tailored to abnormalities found on these initial tests. The combination of metabolic acidosis and an elevated blood glucose strongly suggests diabetic ketoacidosis (DKA) as the etiology of the symptoms; however, it is important to keep in mind that an intra-abdominal infection could precipitate DKA in a patient with diabetes (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"    </a>",
"    ). Adrenal insufficiency should be considered in patients with hyponatremia or hyperkalemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=see_link\">",
"     \"Clinical manifestations of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypercalcemia can cause abdominal pain, either directly or as an etiology for pancreatitis or constipation (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=see_link\">",
"     \"Clinical manifestations of hypercalcemia\"",
"    </a>",
"    ). Hypothyroidism and hyperthyroidism can occasionally cause abdominal pain, and so measurement of thyroid stimulating hormone may be appropriate in patients with other suggestive symptoms or in elderly patients with vague complaints.",
"   </p>",
"   <p>",
"    There may be evidence for hematologic etiologies of generalized abdominal pain, such as severe hemolysis, sickle cell anemia, and acute leukemia on the complete blood count and differential. Even quite unusual causes may have hallmarks, like the microcytic anemia of lead toxicity, which suggests the need for a blood lead level (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link\">",
"     \"Adult lead poisoning\"",
"    </a>",
"    ). Severe intermittent crises of abdominal pain can occur with porphyrias and sickle cell anemia, particularly after an acute precipitant, such as dehydration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link\">",
"     \"Overview of the clinical manifestations of sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=see_link\">",
"     \"Porphyrias: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with suspected acute mesenteric ischemia will generally require an imaging procedure for diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44377?source=see_link\">",
"     \"Acute mesenteric ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     CHRONIC ABDOMINAL PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic abdominal pain is a common complaint, and the vast majority of patients will have a functional disorder, most commonly the irritable bowel syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Initial workup is therefore focused on differentiating benign functional illness from organic pathology. The evaluation of chronic lower abdominal pain (pelvic pain) in women is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41384?source=see_link\">",
"     \"Causes of chronic pelvic pain in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The history should determine the overall time course of the illness, and it should differentiate pain that is fairly constant from pain that is chronic and intermittent. While the hallmark of irritable bowel syndrome is pain associated with changes in bowel habit, other related functional disorders may present with isolated pain (such as functional abdominal pain syndrome) or with pain mimicking upper gastrointestinal organic pathology (such as functional dyspepsia) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=see_link\">",
"     \"Clinical manifestations and diagnosis of irritable bowel syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35272?source=see_link\">",
"     \"Functional dyspepsia\"",
"    </a>",
"    ). A history of recurrent pancreatitis or excessive alcohol intake should raise suspicion for chronic pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30935?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic pancreatitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Features that suggest organic illness include unstable vital signs, weight loss, fever, dehydration, electrolyte abnormalities, symptoms or signs of gastrointestinal blood loss, anemia, or signs of malnutrition.",
"   </p>",
"   <p>",
"    The bowel habit is an important part of the history for chronic abdominal pain. While many organic lesions can result in chronic diarrhea, irritable bowel syndrome often presents with swings between diarrhea and constipation, a pattern that is much less likely with organic disease.",
"   </p>",
"   <p>",
"    The clinician must be alert to the common patterns of presentation in functional abdominal pain. Patients often describe their pain in unusual and dramatic fashion, and they may describe very longstanding pain as having particular urgency at the time of the physician encounter. Unrealistic expectations are common, and patients may demand immediate relief from a problem that has bothered them for years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physical examination must be complete, since many multisystem illnesses could contribute to a nonspecific abdominal complaint. Specifically, the physical examination should clarify any focus of abdominal tenderness that may merit and focus further investigation. Weight should be followed over time, and evidence of dehydration (such as orthostatic changes in vital signs) should be sought. Focal pain that worsens when the patient flexes their abdominal muscles is suggestive of abdominal wall pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31030?source=see_link\">",
"     \"Chronic abdominal wall pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Initial diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following laboratory measurements should be performed in most patients with chronic abdominal pain:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count with differential",
"     </li>",
"     <li>",
"      Electrolytes, BUN, creatinine, and glucose",
"     </li>",
"     <li>",
"      Calcium",
"     </li>",
"     <li>",
"      Aminotransferases, alkaline phosphatase, and bilirubin",
"     </li>",
"     <li>",
"      Lipase",
"     </li>",
"     <li>",
"      Ferritin",
"     </li>",
"     <li>",
"      Anti- tissue transglutaminase",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A complete blood count can reveal anemia or an elevated white blood cell count, and it will occasionally demonstrate elevated platelet counts that may be associated with iron deficiency or inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/45\">",
"     45",
"    </a>",
"    ]. A low ferritin suggests iron deficiency, which should raise the suspicion of celiac disease or inflammatory bowel disease. The above studies should be normal in patients with functional abdominal pain.",
"   </p>",
"   <p>",
"    Abdominal pain is not a common presentation of hyper- or hypothyroidism, but when additional symptoms suggest abnormalities of thyroid function, a thyroid stimulating hormone (TSH) should be measured.",
"   </p>",
"   <p>",
"    Patients with puzzling chronic abdominal pain should have a measurement of antibodies associated with celiac disease (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link&amp;anchor=H22#H22\">",
"     \"Diagnosis of celiac disease\", section on 'Summary and recommendations'",
"    </a>",
"    ), since this is a treatable etiology of abdominal pain that may present at any age [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/46\">",
"     46",
"    </a>",
"    ]. C-reactive protein and ESR are sensitive but nonspecific markers that may suggest the presence of occult organic disease and that have some utility in ruling out organic causes of chronic abdominal pain and diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?18/36/19018/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Subsequent diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the conclusion of the initial workup, young patients with no evidence of organic disease can be treated symptomatically. The use of further invasive testing should be directed at ruling in or out specific diseases and not as a general screen.",
"   </p>",
"   <p>",
"    Although patients with apparently functional abdominal pain have normal investigations and a benign prognosis, they often respond with dissatisfaction and distrust towards physicians who tell them that \"nothing is wrong.\" Functional bowel diseases are associated with diminished quality of life, work loss, and morbidity, and patients deserve attentive trials of therapy as described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40169?source=see_link\">",
"     \"Treatment of irritable bowel syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35272?source=see_link\">",
"     \"Functional dyspepsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conversely, a diagnosis of new-onset functional illness should be made only with great caution in patients over 50 years of age. These patients, by virtue of their increased risk of malignancy, will likely require abdominal imaging with ultrasound or CT and upper gastrointestinal tract endoscopy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    colonoscopy as their symptoms and signs dictate. Many patients in this age group should have colonoscopy performed for screening purposes independent of symptoms, if this has not been performed previously. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients at average risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients have a history of pain that is likely organic, based on historical features or laboratory abnormalities, but may be difficult to definitively diagnose because the symptoms are intermittent. Examples of such cases include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Right upper quadrant pain after cholecystectomy that mimics biliary colic and could be functional biliary pain; it could also arise from intermittent passage of stones that have formed in the bile ducts, passage of sludge, or sphincter of Oddi dysfunction. Transient elevation of liver enzymes or common bile duct dilatation on ultrasound help to define a subgroup of patients that are likely to benefit from endoscopic retrograde cholangiopancreatography (ERCP) and sphincterotomy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12874?source=see_link\">",
"       \"Clinical manifestations and diagnosis of sphincter of Oddi dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intermittent small bowel obstruction may occur as a result of surgical adhesions, inflammatory bowel disease, or small bowel mass lesions (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=see_link\">",
"       \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"      </a>",
"      ). The symptoms are typically abdominal pain and bloating that follow meals by a reasonably consistent time interval. Weight loss may ensue. Depending on the etiology of the obstruction, evidence of progressive systemic illness may develop. Abdominal CT scanning or small-bowel follow-through may reveal the lesion. In cases where suspicion remains high and initial investigations are normal, a small bowel enteroclysis is a more uncomfortable, but highly sensitive, test for this indication. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=see_link\">",
"       \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Very rare causes of intermittent acute severe abdominal pain should be considered in view of a positive family history (eg, Familial Mediterranean Fever, hereditary angioedema) or potentially involved ethnicity (eg, Sickle cell anemia). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25078?source=see_link\">",
"       \"Clinical manifestations and diagnosis of familial Mediterranean fever\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=see_link\">",
"       \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link\">",
"       \"Overview of the clinical manifestations of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/24/25986?source=see_link\">",
"       \"Patient information: Stomach ache and stomach upset (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/23/42353?source=see_link\">",
"       \"Patient information: Chronic pelvic pain in women (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=see_link\">",
"       \"Patient information: Upper endoscopy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/48/8962?source=see_link\">",
"       \"Patient information: Acute abdomen (belly pain) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/24/5506?source=see_link\">",
"       \"Patient information: Upset stomach (functional dyspepsia) in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/55/32627?source=see_link\">",
"       \"Patient information: Chronic pelvic pain in women (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"       \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal pain is a common problem. Most patients have a benign",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      self-limited etiology, and the initial goal of evaluation is to identify those patients with a serious etiology for their symptoms that may require urgent intervention. Patients with abdominal pain who are acutely ill and unstable require immediate transfer to emergency care for diagnosis and resuscitation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Triage and disposition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial consideration in abdominal pain should be whether the symptoms are acute or chronic. Patients with subacute symptoms must be considered as possibly having etiologies for either acute or chronic pain. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Acute versus chronic pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with acute abdominal pain should first be assessed for a surgical abdomen. Patients with evidence of peritonitis or obstruction should be urgently referred for surgical evaluation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Surgical abdomen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with acute abdominal pain without evidence of a surgical abdomen should be assessed based on the location of their pain. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Acute abdominal pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with chronic abdominal pain have a benign functional disorder such as irritable bowel syndrome or functional dyspepsia. These diagnoses may be made without extensive diagnostic workup in younger patients, but should only be made with caution in those over the age of 50. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Chronic abdominal pain'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=see_link\">",
"       \"Clinical manifestations and diagnosis of irritable bowel syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35272?source=see_link\">",
"       \"Functional dyspepsia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/1\">",
"      Hyams JS, Burke G, Davis PM, et al. Abdominal pain and irritable bowel syndrome in adolescents: a community-based study. J Pediatr 1996; 129:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/2\">",
"      Heading RC. Prevalence of upper gastrointestinal symptoms in the general population: a systematic review. Scand J Gastroenterol Suppl 1999; 231:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/3\">",
"      Jones R, Lydeard S. Irritable bowel syndrome in the general population. BMJ 1992; 304:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/4\">",
"      Sandler RS. Epidemiology of irritable bowel syndrome in the United States. Gastroenterology 1990; 99:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/5\">",
"      Kay L. Prevalence, incidence and prognosis of gastrointestinal symptoms in a random sample of an elderly population. Age Ageing 1994; 23:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/6\">",
"      Fleischer AB Jr, Gardner EF, Feldman SR. Are patients' chief complaints generally specific to one organ system? Am J Manag Care 2001; 7:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/7\">",
"      Yamamoto W, Kono H, Maekawa M, Fukui T. The relationship between abdominal pain regions and specific diseases: an epidemiologic approach to clinical practice. J Epidemiol 1997; 7:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/8\">",
"      Heikkinen M, Pikkarainen P, Eskelinen M, Julkunen R. GPs' ability to diagnose dyspepsia based only on physical examination and patient history. Scand J Prim Health Care 2000; 18:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/9\">",
"      Thomson AB, Barkun AN, Armstrong D, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 2003; 17:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/10\">",
"      B&ouml;hner H, Yang Q, Franke C, et al. Simple data from history and physical examination help to exclude bowel obstruction and to avoid radiographic studies in patients with acute abdominal pain. Eur J Surg 1998; 164:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/11\">",
"      Eskelinen M, Ikonen J, Lipponen P. Usefulness of history-taking, physical examination and diagnostic scoring in acute renal colic. Eur Urol 1998; 34:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/12\">",
"      Trowbridge RL, Rutkowski NK, Shojania KG. Does this patient have acute cholecystitis? JAMA 2003; 289:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/13\">",
"      Thomas SH, Silen W, Cheema F, et al. Effects of morphine analgesia on diagnostic accuracy in Emergency Department patients with abdominal pain: a prospective, randomized trial. J Am Coll Surg 2003; 196:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/14\">",
"      Mahadevan M, Graff L. Prospective randomized study of analgesic use for ED patients with right lower quadrant abdominal pain. Am J Emerg Med 2000; 18:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/15\">",
"      Pace S, Burke TF. Intravenous morphine for early pain relief in patients with acute abdominal pain. Acad Emerg Med 1996; 3:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/16\">",
"      Attard AR, Corlett MJ, Kidner NJ, et al. Safety of early pain relief for acute abdominal pain. BMJ 1992; 305:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/17\">",
"      Zoltie N, Cust MP. Analgesia in the acute abdomen. Ann R Coll Surg Engl 1986; 68:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/18\">",
"      Ranji SR, Goldman LE, Simel DL, Shojania KG. Do opiates affect the clinical evaluation of patients with acute abdominal pain? JAMA 2006; 296:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/19\">",
"      Manterola C, Astudillo P, Losada H, et al. Analgesia in patients with acute abdominal pain. Cochrane Database Syst Rev 2007; :CD005660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/20\">",
"      Jung PJ, Merrell RC. Acute abdomen. Gastroenterol Clin North Am 1988; 17:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/21\">",
"      Obuz F, Terzi C, S&ouml;kmen S, et al. The efficacy of helical CT in the diagnosis of small bowel obstruction. Eur J Radiol 2003; 48:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/22\">",
"      Schermer CR, Hanosh JJ, Davis M, Pitcher DE. Ogilvie's syndrome in the surgical patient: a new therapeutic modality. J Gastrointest Surg 1999; 3:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/23\">",
"      Lam&eacute;ris W, van Randen A, van Es HW, et al. Imaging strategies for detection of urgent conditions in patients with acute abdominal pain: diagnostic accuracy study. BMJ 2009; 338:b2431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/24\">",
"      Cappell MS, Friedel D. Abdominal pain during pregnancy. Gastroenterol Clin North Am 2003; 32:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/25\">",
"      Morino M, Pellegrino L, Castagna E, et al. Acute nonspecific abdominal pain: A randomized, controlled trial comparing early laparoscopy versus clinical observation. Ann Surg 2006; 244:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/26\">",
"      Romagnuolo J, Bardou M, Rahme E, et al. Magnetic resonance cholangiopancreatography: a meta-analysis of test performance in suspected biliary disease. Ann Intern Med 2003; 139:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/27\">",
"      Bytzer P, Hansen JM, Havelund T, et al. Predicting endoscopic diagnosis in the dyspeptic patient: the value of clinical judgement. Eur J Gastroenterol Hepatol 1996; 8:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/28\">",
"      Timmons S, Liston R, Moriarty KJ. Functional dyspepsia: motor abnormalities, sensory dysfunction, and therapeutic options. Am J Gastroenterol 2004; 99:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/29\">",
"      Lewin van den Broek NT, Numans ME, Buskens E, et al. A randomised controlled trial of four management strategies for dyspepsia: relationships between symptom subgroups and strategy outcome. Br J Gen Pract 2001; 51:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/30\">",
"      Yadav D, Agarwal N, Pitchumoni CS. A critical evaluation of laboratory tests in acute pancreatitis. Am J Gastroenterol 2002; 97:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/31\">",
"      Tenner S, Dubner H, Steinberg W. Predicting gallstone pancreatitis with laboratory parameters: a meta-analysis. Am J Gastroenterol 1994; 89:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/32\">",
"      Tabibian N. Endoscopy versus x-ray studies of the gastrointestinal tract: future health care implications. South Med J 1991; 84:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/33\">",
"      Chandie Shaw MP, van Romunde LK, Griffioen G, et al. [Comparison of biphasic radiologic stomach and duodenum studies with fiber endoscopy for the diagnosis of peptic ulcer and stomach carcinoma]. Ned Tijdschr Geneeskd 1990; 134:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/34\">",
"      Oiwa T, Mori M, Sugimachi K, Enjoji M. Diagnostics of small gastric carcinoma. J Surg Oncol 1986; 33:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/35\">",
"      Mori M, Sugimachi K. Clinicopathologic studies of gastric carcinoma. Semin Surg Oncol 1990; 6:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/36\">",
"      Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology 2005; 129:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/37\">",
"      Hammond NA, Nikolaidis P, Miller FH. Left lower-quadrant pain: guidelines from the American College of Radiology appropriateness criteria. Am Fam Physician 2010; 82:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/38\">",
"      Brandt LJ, Boley SJ. AGA technical review on intestinal ischemia. American Gastrointestinal Association. Gastroenterology 2000; 118:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/39\">",
"      Boley SJ, Sprayregen S, Veith FJ, Siegelman SS. An aggressive roentgenologic and surgical approach to acute mesenteric ischemia. Surg Annu 1973; 5:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/40\">",
"      Gennaro M, Ascer E, Matano R, et al. Acute mesenteric ischemia after cardiopulmonary bypass. Am J Surg 1993; 166:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/41\">",
"      Diamond SM, Emmett M, Henrich WL. Bowel infarction as a cause of death in dialysis patients. JAMA 1986; 256:2545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/42\">",
"      Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/43\">",
"      Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ 3rd. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991; 101:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/44\">",
"      Drossman DA. Functional abdominal pain syndrome. Clin Gastroenterol Hepatol 2004; 2:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/45\">",
"      Danese S, Motte Cd Cde L, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol 2004; 99:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/46\">",
"      Zipser RD, Patel S, Yahya KZ, et al. Presentations of adult celiac disease in a nationwide patient support group. Dig Dis Sci 2003; 48:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/36/19018/abstract/47\">",
"      Di Leo V, D'Inc&agrave; R, Diaz-Granado N, et al. Lactulose/mannitol test has high efficacy for excluding organic causes of chronic diarrhea. Am J Gastroenterol 2003; 98:2245.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6862 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-812927D4EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_36_19018=[""].join("\n");
var outline_f18_36_19018=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TRIAGE AND DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ACUTE VERSUS CHRONIC PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ACUTE ABDOMINAL PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Surgical abdomen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Peritonitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Initial diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Subsequent diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Right upper quadrant pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Initial diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Subsequent diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Epigastric pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Nonabdominal etiologies of upper abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Diagnostic testing for pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Diagnostic testing for dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Lower abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Nonabdominal etiologies of lower abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Lower abdominal pain in women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Generalized abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      CHRONIC ABDOMINAL PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Initial diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Subsequent diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31370?source=related_link\">",
"      Acute appendicitis in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=related_link\">",
"      Acute cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/50/22311?source=related_link\">",
"      Acute colonic pseudo-obstruction (Ogilvie's syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44377?source=related_link\">",
"      Acute mesenteric ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=related_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=related_link\">",
"      Adult lead poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32025?source=related_link\">",
"      Approach to the adult with acute diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=related_link\">",
"      Approach to the patient with an adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=related_link\">",
"      Approach to the patient with dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43032?source=related_link\">",
"      Approach to the woman with sexual pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41384?source=related_link\">",
"      Causes of chronic pelvic pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31030?source=related_link\">",
"      Chronic abdominal wall pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=related_link\">",
"      Clinical features and diagnosis of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=related_link\">",
"      Clinical manifestations and diagnosis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30935?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic pancreatitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34919?source=related_link\">",
"      Clinical manifestations and diagnosis of colonic diverticular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25078?source=related_link\">",
"      Clinical manifestations and diagnosis of familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=related_link\">",
"      Clinical manifestations and diagnosis of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12874?source=related_link\">",
"      Clinical manifestations and diagnosis of sphincter of Oddi dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=related_link\">",
"      Clinical manifestations of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=related_link\">",
"      Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17946?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/17/7450?source=related_link\">",
"      Definition, epidemiology, and risk factors in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=related_link\">",
"      Diagnosis and acute management of suspected nephrolithiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=related_link\">",
"      Differential diagnosis of abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24265?source=related_link\">",
"      Differential diagnosis of microbial foodborne disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=related_link\">",
"      Differential diagnosis of the adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37175?source=related_link\">",
"      Endoscopic balloon dilatation for removal of bile duct stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43557?source=related_link\">",
"      Endoscopic ultrasound in patients with suspected choledocholithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4489?source=related_link\">",
"      Epidemiology of and risk factors for gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=related_link\">",
"      Etiology of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35272?source=related_link\">",
"      Functional dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=related_link\">",
"      Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40323?source=related_link\">",
"      History and physical examination in adults with abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=related_link\">",
"      Management of asymptomatic abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/48/8962?source=related_link\">",
"      Patient information: Acute abdomen (belly pain) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/55/32627?source=related_link\">",
"      Patient information: Chronic pelvic pain in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/23/42353?source=related_link\">",
"      Patient information: Chronic pelvic pain in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/24/25986?source=related_link\">",
"      Patient information: Stomach ache and stomach upset (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/24/5506?source=related_link\">",
"      Patient information: Upset stomach (functional dyspepsia) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=related_link\">",
"      Porphyrias: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/60/39879?source=related_link\">",
"      Primary dysmenorrhea in adult women: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients at average risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=related_link\">",
"      Small bowel obstruction: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42681?source=related_link\">",
"      The gynecologic history and pelvic examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40169?source=related_link\">",
"      Treatment of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21992?source=related_link\">",
"      Ultrasonography of the hepatobiliary tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=related_link\">",
"      Uncomplicated gallstone disease in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_36_19019="Less com pathogens after BMT-III";
var content_f18_36_19019=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Less common pathogens to cause infections in bone marrow/stem cell transplant recipients not receiving standard prophylaxis-III",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Late postengraftment (allogeneic BMT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Same as preengraftment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Fungi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Same as preengraftment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parvovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        BK/JC virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatitis B, C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Protozoa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Same as immediate postengraftment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Mycobacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Same as immediate postengraftment",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_36_19019=[""].join("\n");
var outline_f18_36_19019=null;
var title_f18_36_19020="Causes of pediatric hyperkalemia";
var content_f18_36_19020=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F85965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F85965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of hyperkalemia in children based on pathophysiology",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cause",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Increased potassium intake (rare cause of hyperkalemia with the exception of children with chronic kidney disease)",
"       </td>",
"       <td>",
"        Exposure to high potassium loads in intravenous fluids or medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exposure to potassium containing medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Massive transfusions of stored blood",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Transcellular potassium movement",
"       </td>",
"       <td>",
"        Structural cellular damage due to:",
"        <ul>",
"         <li>",
"          Hemolysis",
"         </li>",
"         <li>",
"          Rhabdomyolysis",
"         </li>",
"         <li>",
"          Tumor lysis",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No structural cellular injury:",
"        <ul>",
"         <li>",
"          Metabolic acidosis",
"         </li>",
"         <li>",
"          Diabetic ketoacidosis",
"         </li>",
"         <li>",
"          Hyperkalemia periodic paralysis",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Abnormal renal potassium excretion",
"       </td>",
"       <td>",
"        Decreased effective circulating volume",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased RAAS activity:",
"        <ul>",
"         <li>",
"          Congenital adrenal hyperplasia",
"         </li>",
"         <li>",
"          Adrenal insufficiency",
"         </li>",
"         <li>",
"          Drug effect (ACE inhibitor/ARB, eplerenone, spironolactone, or aliskiren)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Significant renal impairment with either acute or chronic loss of GFR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impaired tubular potassium secretion:",
"        <ul>",
"         <li>",
"          Reflux nephropathy",
"         </li>",
"         <li>",
"          Obstructive uropathy",
"         </li>",
"         <li>",
"          Sickle cell nephropathy",
"         </li>",
"         <li>",
"          Drug effect (amiloride, triamterene)",
"         </li>",
"         <li>",
"          Hypoaldosteronism (type IV renal tubular acidosis)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Pseudohyperkalemia",
"       </td>",
"       <td>",
"        Hemolyzed specimen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukocytosis or thrombocytosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RAAS: renin-angiotensin-aldosterone system; ACE inhibitor/ARB: angiotensin converting enzyme inhibitor/angiotensin receptor blocker; GFR: glomerular filtration rate.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_36_19020=[""].join("\n");
var outline_f18_36_19020=null;
var title_f18_36_19021="CT treatment of osteoporosis";
var content_f18_36_19021=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F73907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F73907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Calcitonin reduces vertebral fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 248px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Change in the spinal deformity index (SDI, with a higher value reflecting more deformity) in 72 postmenopausal women with osteoporosis treated with calcium alone or with nasal salmon calcitonin. There was less deformity in the calcitonin group (p &lt;0.001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Rico, H, Revilla, M, Hernandez, ER, et al, Calcif Tissue Int 1995; 56:181.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_36_19021=[""].join("\n");
var outline_f18_36_19021=null;
var title_f18_36_19022="QT dispersion VT";
var content_f18_36_19022=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 588px\">",
"   <div class=\"ttl\">",
"    QT dispersion in patients with and without ventricular tachycardia is variable",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 568px; height: 266px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A summary of studies evaluating QT dispersion in patients with (red) and without (blue) ventricular tachyarrhythmias demonstrates a great degree of overlap in the mean QT dispersion. Some, but not all studies, have shown that the mean QT dispersion is greater in patients with ventricular arrhythmias compared to those without ventricular arrhythmia.",
"    <div class=\"footnotes\">",
"     NS: nonsignificant.",
"     <br>",
"      * p = 0.05.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_36_19022=[""].join("\n");
var outline_f18_36_19022=null;
var title_f18_36_19023="Arteriovenous anastomosis preablation";
var content_f18_36_19023=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Arteriovenous anastomosis preablation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The vessel at 11 o'clock is the recipient's vein, the vessel coming in at 5 o'clock is the donor artery, the \"green\" targeting light is focused on the donor vessel.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kenneth J Moise, Jr, MD and Anthony Johnson, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_36_19023=[""].join("\n");
var outline_f18_36_19023=null;
